Introduction {#S1}
============

Neuroinflammation after traumatic brain injury (TBI) is postulated to be a key driver of secondary brain injury in the acute/subacute phase after injury ([@B1], [@B2]). Upregulation of various components of the inflammatory cascade have been associated with lesion expansion ([@B3]), cerebral edema ([@B4]), derangements in neural transmission ([@B5]), and subsequent tissue death ([@B6]) in animal models of stroke and TBI. In humans, the inflammatory process post-TBI has been of interest, since its therapeutic modulation can potentially lead to amelioration of pathophysiology, tissue salvage, and improved patient outcomes ([@B7], [@B8]). Serum cytokine levels are easily measured in TBI patients, and elevation in pro-inflammatory cytokines have been associated with worse patient outcome ([@B9], [@B10]). However, systemic cytokine levels can be confounded by extracranial pathology and variable blood--brain barrier leak of centrally derived mediators. Measurement of cerebral levels of cytokines provides a more direct metric of neuroinflammation following TBI, but, to date, the measurement of cerebral microdialysis (CMD) ([@B11]--[@B29]) and cerebrospinal fluid (CSF) ([@B30]--[@B65]) cytokines have been limited to small studies.

The goal of this study was to produce a scoping systematic review of the literature on both CMD and CSF cytokines in severe TBI (sTBI). Our hope was to produce a comprehensive overview of the literature on this emerging topic.

Methods {#S2}
=======

Two separate scoping systematic reviews were conducted, using the methodology outlined in the Cochrane Handbook for Systematic Reviewers ([@B66]). Data were reported following the preferred reporting items for systematic reviews and meta-analyses ([@B67]). The review questions and search strategy were decided upon by the primary author (Frederick A. Zeiler) and supervisors (Adel Helmy and David K. Menon).

This manuscript was conducted in concert with a similar review on cytokines in CMD and CSF for aneurysmal subarachnoid hemorrhage (SAH) patients.

Search Question and Population of Interest {#S2-1}
------------------------------------------

Given that two separate systematic reviews were conducted, one for CMD cytokines and the other for CSF cytokines, two distinct questions were posed. The limited literature on CMD cytokines identified through a preliminary search of PubMed led us to conduct a scoping review for the CMD cytokine search. We attempted to identify all studies in this area to date, and all articles describing microdialysis cytokine measures in humans with sTBI included in our review in order to provide a comprehensive overview of this emerging area of literature. The key question for this part of the review was: What literature has been published on CMD of cytokines in sTBI?

The larger literature base for CSF cytokines in TBI led us to narrow our question for this scoping review, focusing on relevant outcomes (see below). The questions posed for this scoping systematic review was: Is there literature to suggest an association between CSF cytokine measures in sTBI and patient outcome, neurophysiologic outcome, or tissue outcome?

For the CSF cytokine review, the primary outcome measures were documented association between CSF cytokine levels and: patient outcome, neurophysiologic outcome (as measured *via* intensive care unit (ICU)-based monitoring; intracranial pressure (ICP)/cerebral perfusion pressure (CPP), brain tissue oxygen monitoring (PbtO~2~), thermal diffusion assessment of cerebral blood flow (CBF), transcranial Doppler (TCD) measure of cerebral blood flow velocity (CBFV), any neuroimaging based assessment of CBF/perfusion, and electrophysiology), and tissue outcome \[as assessed on follow-up neuroimaging by either computed tomography (CT) or magnetic resonance imaging\]. Any outcome score or mention of morbidity/mortality within the studies was deemed acceptable for documentation of patient outcome. Secondary outcome measures were complications associated with CSF monitoring of cytokines.

The list of included cytokines in CMD or CSF included: interleukin (IL)-1a, IL-1b, IL-1ra, IL-2, sIL-2ra, IL-3, IL-4, IL-5, IL-6, IL-7, IL-8, IL-9, IL-10, IL-11, IL-12, IL-12p70, IL-13, IL-14, IL-15, IL-16, IL-17, inducible protein (IP)-10, eotaxin, tumor necrosis factor (TNF), interferon gamma (INF-g), monocyte chemoattractant proteins, macrophage inflammatory proteins (MIPs), transforming growth factor (TGF), nerve growth factor (NGF), brain-derived neurotrophic factor, glial-derived neurotrophic factor, soluble tumor necrosis factor receptor (sTNFR), granulocyte macrophage colony stimulating factor, soluble FAS, soluble vascular cell adhesion molecule (sVCAM)-1, and soluble intracellular adhesion molecule (sICAM)-1, platelet-derived growth factor, regulated on activation, normal T cell expressed and secreted (RANTES), macrophage-derived chemokine (MDC), fms-like tyrosine kinase 3 (Flt3), Fractalkine, and fibroblast growth factor receptor.

Inclusion/Exclusion Criteria {#S2-2}
----------------------------

### CMD Cytokine Review {#S2-2-1}

Inclusion criteria were: all studies including human subjects with sTBI (GCS 8 or less), any study size, any age category, CMD analysis for cytokines, and mention of any outcome (patient based or otherwise). Exclusion criteria were: non-English studies and animal studies.

### CSF Cytokine Review {#S2-2-2}

Inclusion criteria were: all studies including human subjects with sTBI (GCS of 8 or less), studies with 10 or more patients, any age category, CSF analysis for cytokines, and documentation either: patient functional outcome, neurophysiologic outcome, or tissue outcome in relation to CSF cytokine measures. Exclusion criteria were: non-English studies, animal studies, and studies of less than 10 patients. Non-English studies were excluded given the small number identified.

Search Strategies {#S2-3}
-----------------

MEDLINE, BIOSIS, EMBASE, Global Health, SCOPUS, and Cochrane Library from inception to October 2016 were searched using individualized search strategies. The search strategy for the CMD scoping systematic review using MEDLINE can be seen in Appendix A in Supplementary Material, with a similar search strategy utilized for the other databases. Further, the search strategy for the CSF scoping systematic review using MEDLINE can be seen in Appendix B in Supplementary Material, with similar strategies employed for the other databases.

In addition, we surveyed relevant meeting proceedings for the last 5 years looking for ongoing and unpublished work based on cytokine analysis *via* CMD or CSF in sTBI patients. The meeting proceedings of the following professional societies were searched: Canadian Neurological Sciences Federation, American Association of Neurological Surgeons, Congress of Neurological Surgeons, European Neurosurgical Society, World Federation of Neurological Surgeons, National Neurotrauma Society, American Neurology Association, American Academy of Neurology, European Federation of Neurological Science, World Congress of Neurology, Society of Critical Care Medicine, Neurocritical Care Society, European Society for Intensive Care Medicine, World Federation of Societies of Intensive and Critical Care Medicine, American Society for Anesthesiologists, World Federation of Societies of Anesthesiologist, Australian Society of Anesthesiologists, International Anesthesia Research Society, Society of Neurosurgical Anesthesiology and Critical Care, Society for Neuroscience in Anesthesiology and Critical Care, Japanese Society of Neuroanesthesia and Critical Care, International NeuroTrauma Society, International Brain Injury Association, and the College of Intensive Care Medicine Annual Scientific Meeting (CICMASM---Australia).

Finally, reference lists of any review articles on CSF or CMD cytokines were reviewed for any missed relevant studies.

Study Selection {#S2-4}
---------------

Utilizing two reviewers, a two-step review of all articles returned by our search strategies was performed. First, the reviewers independently (Frederick A. Zeiler and Eric Peter Thelin) screened titles and abstracts of the returned articles to decide if they met the inclusion criteria. Second, full text of the chosen articles was then assessed to confirm if they met the inclusion criteria and that the primary outcomes of interest were reported in the study (Frederick A. Zeiler and Eric Peter Thelin). Any discrepancies between the two reviewers were resolved by a third reviewer if needed (Adel Helmy or David K. Menon).

Data Collection {#S2-5}
---------------

Data were extracted from the selected articles and stored in an electronic database. Data fields included: patient demographics, type of study, article location, number of patients, CMD/CSF substrate measured, CMD/CSF measurement details (probe tissue location, sampling frequency), outcome measure described (patient, neurophysiologic, tissue), association between CMD/CSF cytokine measure to outcome, and complications. All extracted data can be found in Tables [1](#T1){ref-type="table"} through [4](#T4){ref-type="table"}, with study designs in Tables [1](#T1){ref-type="table"} and [2](#T2){ref-type="table"}, and study outcomes in Tables [3](#T3){ref-type="table"} and [4](#T4){ref-type="table"}.

###### 

CMD cytokine study characteristics and patient demographics.

  Reference                                                                                    Number of patients                            Study type                        Article location   Mean age (years)                   Patient characteristics                                              Primary and secondary goal of study
  -------------------------------------------------------------------------------------------- --------------------------------------------- --------------------------------- ------------------ ---------------------------------- -------------------------------------------------------------------- ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Cederberg et al. ([@B11])                                                                    7                                             Retrospective case series         Meeting abstract   Unknown "children"                 Severe TBI; 3 underwent DC                                           Primary: to compare CMD cytokines to common CMD measures, PbtO~2~, and ICP
  Secondary: none mentioned                                                                                                                                                                                                                                                                               
                                                                                                                                                                                                                                                                                                          
  Figaji et al. ([@B12])                                                                       5                                             Unknown                           Meeting abstract   Unknown "children"                 Severe TBI                                                           Primary: to compare CMD cytokine and other CMD measures
  Secondary: none mentioned                                                                                                                                                                                                                                                                               
                                                                                                                                                                                                                                                                                                          
  Guilfoyle et al. ([@B13])                                                                    12                                            Prospective observational         Meeting abstract   Unknown "adults"                   Severe TBI                                                           Primary: to compared CMD cytokine measures in healthy vs. peri-lesional tissue
  Secondary: none mentioned                                                                                                                                                                                                                                                                               
                                                                                                                                                                                                                                                                                                          
  [^a^](#tfn1){ref-type="table-fn"}Helmy et al. ([@B14])                                       12                                            Prospective observational         Manuscript         Unknown "adults"                   Severe TBI                                                           Primary: to perform a principle component analysis of CMD cytokines to determine cytokine patterns and temporal profiles
  Secondary: none mentioned                                                                                                                                                                                                                                                                               
                                                                                                                                                                                                                                                                                                          
  [^a^](#tfn1){ref-type="table-fn"}Helmy et al. ([@B15])                                       12                                            Prospective observational         Manuscript         Unknown "adults"                   Severe TBI                                                           Primary: 1. To compare crystalloid vs. albumin perfusate in CMD cytokine recovery. 2. To compare the cytokine profile in sTBI
  Secondary: not specified                                                                                                                                                                                                                                                                                
                                                                                                                                                                                                                                                                                                          
  [^b^](#tfn2){ref-type="table-fn"}Helmy et al. ([@B16])                                       20                                            Prospective RCT                   Manuscript         38.9 years (range: 18--61 years)   Severe diffuse TBI; randomized to subcutaneous rhIL-1ra              Primary: 1. To provide safety data in a randomized fashion on rhIL-1ra in sTBI
  2\. To describe the impact of rhIL-1ra on CMD cytokine profiles                                                                                                                                                                                                                                         
  Secondary: none mentioned                                                                                                                                                                                                                                                                               
                                                                                                                                                                                                                                                                                                          
  [^b^](#tfn2){ref-type="table-fn"}Helmy et al. ([@B17])                                       20                                            Retrospective database analysis   Manuscript         38.9 years (range: 18--61 years)   Severe diffuse TBI; randomized to subcutaneous rhIL-1ra              Primary: to retrospectively analyze RCT data on rhIL-1ra administration, to better delineate the temporal change in cytokine profiles
  Secondary: none mentioned                                                                                                                                                                                                                                                                               
                                                                                                                                                                                                                                                                                                          
  Hillman et al. ([@B18])                                                                      9 (10 total, but failed CMD catheter in 1)    Prospective observational         Manuscript         Unknown                            Severe brain injury (undisclosed number of aSAH and sTBI patients)   Primary: to evaluate newer microdialysis catheters and their ability to measure various CMD macromolecules (including IL-6) vs. older catheters. Varied perfusates were also analyzed
  Secondary: none mentioned                                                                                                                                                                                                                                                                               
                                                                                                                                                                                                                                                                                                          
  Hillman et al. ([@B19])                                                                      7 with TBI (14 total; mixed injury sources)   Prospective observational         Manuscript         Unknown                            sTBI---5 requiring "surgery"                                         Primary: to determine the CMD cytokine patterns in TBI
  Secondary: none mentioned                                                                                                                                                                                                                                                                               
                                                                                                                                                                                                                                                                                                          
  Hutchinson et al. ([@B20])                                                                   15                                            Prospective observational         Manuscript         41 years (range: 17--68 years)     Severe TBI                                                           Primary: to determine the feasibility of measures IL-1a, IL-1b, and IL-1ra in CMD samples
  Secondary: correlation of cytokine to ICP, CPP, and patient outcome                                                                                                                                                                                                                                     
                                                                                                                                                                                                                                                                                                          
  Mellergard et al. ([@B21])                                                                   7 (total 38 patients; only 7 with TBI)        Prospective observational         Manuscript         Unknown                            Severe TBI                                                           Primary: to evaluate CMD cytokine profiles immediately after insertion of the CMD catheter
  Secondary: none mentioned                                                                                                                                                                                                                                                                               
                                                                                                                                                                                                                                                                                                          
  [^c^](#tfn3){ref-type="table-fn"}Mellergard et al. ([@B22])                                  57 (total 145 patients; only 57 with TBI)     Retrospective case series         Manuscript         Unknown                            Severe TBI                                                           Primary: to determine the CMD cytokine responds to TBI
  Secondary: none mentioned                                                                                                                                                                                                                                                                               
                                                                                                                                                                                                                                                                                                          
  [^c^](#tfn3){ref-type="table-fn"}Mellergard et al. ([@B23])                                  57 (total 145 patients; only 57 with TBI)     Retrospective case series         Manuscript         Unknown                            Severe TBI                                                           Primary: to determine the CMD cytokine responds to TBI
  Secondary: none mentioned                                                                                                                                                                                                                                                                               
                                                                                                                                                                                                                                                                                                          
  Mellergard et al. ([@B24])                                                                   69                                            Unknown                           Manuscript         45.9 years (range: unknown)        Severe TBI                                                           Primary: to determine if there is age-related difference in CMD cytokines
  Secondary: none mentioned                                                                                                                                                                                                                                                                               
                                                                                                                                                                                                                                                                                                          
  Mondello et al. ([@B25])                                                                     6                                             Prospective observational         Meeting abstract   Unknown                            Severe TBI                                                           Primary: to evaluate the temporal profile of CMD and CSF cytokines in TBI
  Secondary: none mentioned                                                                                                                                                                                                                                                                               
                                                                                                                                                                                                                                                                                                          
  Parez-Barcena et al. ([@B26])                                                                16                                            Prospective observational         Manuscript         31.8 years (range: 16--65 years)   Severe diffuse TBI                                                   Primary: to determine the cytokine profiles in severe diffuse TBI patients
  Secondary: to determine the correlation between cytokines and ICP, PbtO~2~, and CT changes                                                                                                                                                                                                              
                                                                                                                                                                                                                                                                                                          
  Roberts et al. ([@B27])                                                                      8                                             Prospective observational         Manuscript         43.4 years (range: unknown)        Severe TBI                                                           Primary: to measure the blood/CSF/CMD MMP and cytokine response post-TBI
  Secondary: correlation to neurologic exam, ICP, PbtO~2~, GOS at discharge                                                                                                                                                                                                                               
                                                                                                                                                                                                                                                                                                          
  Winter et al. ([@B28])                                                                       3                                             Prospective observational         Manuscript         Unknown                            Severe TBI                                                           Primary: to describe the technique of cytokine measurement *via* CMD
  Secondary: describe cytokine patterns in TBI                                                                                                                                                                                                                                                            
                                                                                                                                                                                                                                                                                                          
  Winter et al. ([@B29])                                                                       14                                            Prospective observational         Manuscript         43.1 years (range: 21--77 years)   Severe TBI                                                           Primary: to evaluate the changes in CMD cytokines post-TBI
  Secondary: correlation to patient outcome                                                                                                                                                                                                                                                               

*TBI, traumatic brain injury; sTBI, severe TBI; aSAH, aneurysmal subarachnoid hemorrhage; DC, decompressive craniectomy; CMD, cerebral microdialysis; RCT, randomized control trial; ICP, intracranial pressure; CPP, cerebral perfusion pressure; CSF, cerebrospinal fluid; LPR, lactate:pyruvate ratio; CT, computed tomography; PbtO~2~, partial pressure of oxygen in brain tissue; MMPs, matrix metalloproteins, IL, interleukin; a, alpha; b, beta; ra, receptor anatogonist; rh, recombinant human*.

*^a^Same patient population reported in both Helmy et al. ([@B14]) and Helmy et al. ([@B15])*.

*^b^Same patient population described in Helmy et al. ([@B16]) and Helmy et al. ([@B17])*.

*^c^Same patient population reported in both Mellergard et al. ([@B22]) and Mellergard et al. ([@B23])*.

###### 

CSF cytokine study characteristics and patient demographics.

  Reference                                                                                                                                       Number of patients                                                          Study type                  Article location   Mean age (years)                           Patient characteristics                                  Primary and secondary goal of study
  ----------------------------------------------------------------------------------------------------------------------------------------------- --------------------------------------------------------------------------- --------------------------- ------------------ ------------------------------------------ -------------------------------------------------------- -------------------------------------------------------------------------------------------------------------------------------------------------------------
  **Patient functional outcome**                                                                                                                                                                                                                                                                                                                                                 
  Abboud et al. ([@B30])                                                                                                                          31                                                                          Prospective observational   Manuscript         31.6 years (range: unknown)                Severe TBI                                               Primary: to describe the correlation between CSF cytokine profiles and outcome at 6 and 12 months
  Secondary: none mentioned                                                                                                                                                                                                                                                                                                                                                      
                                                                                                                                                                                                                                                                                                                                                                                 
  Bell et al. ([@B31])                                                                                                                            15                                                                          Prospective observational   Manuscript         6.1 years (range: 0.1--16 years)           Severe TBI                                               Primary: to determine the relationship between IL-6 and IL-10 with patient outcome
  Secondary: to compare CSF cytokine levels to non-TBI control subjects (*n* = 20)                                                                                                                                                                                                                                                                                               
                                                                                                                                                                                                                                                                                                                                                                                 
  Chiaretti et al. ([@B32])                                                                                                                       29                                                                          Prospective observational   Manuscript         9.7 years (range: 1.3--15.6 years)         Severe TBI                                               Primary: to determine the association between IL-6 and patient outcome
  Secondary: to determine the correlation between IL-6 and NGF in CSF. Also to compare to non-TBI control patients (*n* = 31)                                                                                                                                                                                                                                                    
                                                                                                                                                                                                                                                                                                                                                                                 
  Chiaretti et al. ([@B33])                                                                                                                       27                                                                          Prospective observational   Manuscript         8.6 years (range: 1.3--15.6)               Severe TBI                                               Primary: to determine the association between IL-1b, IL-6, NGF, BDNF, and GDNF with patient outcome
  Secondary: none mentioned                                                                                                                                                                                                                                                                                                                                                      
                                                                                                                                                                                                                                                                                                                                                                                 
  Chiaretti et al. ([@B34])                                                                                                                       14                                                                          Prospective observational   Manuscript         7.8 years (range: 0.3--15.6 years)         Severe TBI                                               Primary: to determine the relationship between IL-1b and IL-6 with patient outcome
  Secondary: to compared cytokine expression to obstructive hydrocephalus controls                                                                                                                                                                                                                                                                                               
                                                                                                                                                                                                                                                                                                                                                                                 
  Hans et al. ([@B35])                                                                                                                            11                                                                          Prospective observational   Manuscript         36.7 years (range: 16--67)                 Severe TBI                                               Primary: to determine the association between IL-6 and sIL-6R to patient outcome
  Secondary: to compare these CSF cytokine levels to those in plasma                                                                                                                                                                                                                                                                                                             
                                                                                                                                                                                                                                                                                                                                                                                 
  Hayakata et al. ([@B36])                                                                                                                        53                                                                          Prospective observational   Manuscript         34--49 years                               Severe TBI                                               Primary: to determine the association between TNF-a, IL-1, IL-6, IL-8, and IL-10 with patient outcome
  Secondary: to determine the association between cytokines and S100B expression in CSF. Also compare cytokines to ICP                                                                                                                                                                                                                                                           
                                                                                                                                                                                                                                                                                                                                                                                 
  Jamil et al. ([@B37])                                                                                                                           61                                                                          Prospective observational   Meeting abstract   Unknown "adults"                           Severe TBI                                               Primary: to determine the relationship between acute measures of CSF cytokines and PTD at 6 and 12 months
  Secondary: none mentioned                                                                                                                                                                                                                                                                                                                                                      
                                                                                                                                                                                                                                                                                                                                                                                 
  Juengst et al. ([@B38])                                                                                                                         25                                                                          Prospective observational   Meeting abstract   Unknown "adults"                           Severe TBI                                               Primary: to determine the association between acute cytokine levels and apathy at 6 and 12 months post-injury
  Secondary: none mentioned                                                                                                                                                                                                                                                                                                                                                      
                                                                                                                                                                                                                                                                                                                                                                                 
  Juengst et al. ([@B39])                                                                                                                         37                                                                          Prospective observational   Manuscript         "Adults"                                   Moderate--severe TBI                                     Primary: to determine the relationship between TNF-a and disinhibition/suicidality post-TBI
  Unclear overall mean age                                                                                                                        Secondary: compare levels in CSF and serum to healthy controls (*n* = 15)                                                                                                                                                      
                                                                                                                                                                                                                                                                                                                                                                                 
  Juengst et al. ([@B40])                                                                                                                         50                                                                          Prospective observational   Manuscript         31.3 years (range: unknown)                Severe TBI                                               Primary: to determine the relationship between acute CSF cytokine profiles and the risk of PTD at 6 and 12 months post-injury
  Secondary: none mentioned                                                                                                                                                                                                                                                                                                                                                      
                                                                                                                                                                                                                                                                                                                                                                                 
  Kirchhoff et al. ([@B41])                                                                                                                       23                                                                          Prospective observational   Meeting abstract   Unknown                                    Severe TBI                                               Primary: to determine the IL-10 response in CSF in TBI patients. Also determine the relationship to outcome.
  Secondary: compared CSF in TBI to elective surgical patients (*n* = 10)                                                                                                                                                                                                                                                                                                        
                                                                                                                                                                                                                                                                                                                                                                                 
  Kossmann et al. ([@B42])                                                                                                                        22                                                                          Prospective observational   Manuscript         41 years (range: 17--73)                   Severe TBI                                               Primary: to determine the relationship between CSF IL-6 and NGF. Also determine the association to patient outcome.
  Secondary: compare IL-6 and NGF in controls (*n* = 3)                                                                                                                                                                                                                                                                                                                          
                                                                                                                                                                                                                                                                                                                                                                                 
  Kumar et al. ([@B43])                                                                                                                           114                                                                         Prospective observational   Manuscript         Unclear overall mean age                   Severe TBI                                               Primary: to determine the relationship of IL-6 in CSF to serum values and patient outcome
  Secondary: compare CSF levels in non-TBI controls (*n* = 23)                                                                                                                                                                                                                                                                                                                   
                                                                                                                                                                                                                                                                                                                                                                                 
  Kumar et al. ([@B44])                                                                                                                           111                                                                         Prospective observational   Manuscript         Unknown (range: 16--75)                    Severe TBI                                               Primary: to utilize PCA to determine clusters of cytokines associated with patient outcome
  Secondary: to determine a temporal patter of cytokine clusters and relationship to outcome                                                                                                                                                                                                                                                                                     
                                                                                                                                                                                                                                                                                                                                                                                 
  Kushi et al. ([@B45])                                                                                                                           22                                                                          Prospective observational   Manuscript         45 years (range: unknown)                  Severe TBI                                               Primary: to compare CSF and Serum IL-6/IL-8 levels and determine the association to patient outcome
  Secondary: none mentioned                                                                                                                                                                                                                                                                                                                                                      
                                                                                                                                                                                                                                                                                                                                                                                 
  Nwachuku et al. ([@B46])                                                                                                                        32                                                                          Prospective observational   Manuscript         31 years (range: unknown)                  Severe TBI                                               Primary: to determine the association between various CSF cytokines and patient outcome
  Secondary: none mentioned                                                                                                                                                                                                                                                                                                                                                      
                                                                                                                                                                                                                                                                                                                                                                                 
  Santarseiri et al. ([@B47])                                                                                                                     91                                                                          Prospective observational   Manuscript         35.8 years (range: 16--73)                 Severe TBI                                               Primary: to identify CSF cytokines associated with patient outcome. Also determine association between cytokines and neuroendocrine cortisol function
  Secondary: none mentioned                                                                                                                                                                                                                                                                                                                                                      
                                                                                                                                                                                                                                                                                                                                                                                 
  Shiozaki et al. ([@B48])                                                                                                                        35                                                                          Prospective observational   Manuscript         39 years (range: 14--77 years)             Severe TBI                                               Primary: to determine the association between CSF cytokine profiles and patient outcome
  Secondary: to determine the association between cytokines and ICP                                                                                                                                                                                                                                                                                                              
                                                                                                                                                                                                                                                                                                                                                                                 
  Singhal et al. ([@B49])                                                                                                                         36                                                                          Prospective observational   Manuscript         34.4 years (range: 17--68 years)           Severe TBI                                               Primary: to determine the association between cytokines and electrophysiologic/functional patient outcome
  Secondary: none mentioned                                                                                                                                                                                                                                                                                                                                                      
                                                                                                                                                                                                                                                                                                                                                                                 
  Whalen et al. ([@B50])                                                                                                                          27                                                                          Prospective observational   Manuscript         Unknown "children"                         Severe TBI                                               Primary: to determine the association between CSF IL-8 levels and patient outcome
  Secondary: to determine the association between CSF IL-8 in TBI patients and non-TBI controls (*n* = 24)                                                                                                                                                                                                                                                                       
                                                                                                                                                                                                                                                                                                                                                                                 
  **Neurophysiologic association**                                                                                                                                                                                                                                                                                                                                               
                                                                                                                                                                                                                                                                                                                                                                                 
  Muller et al. ([@B51])                                                                                                                          25                                                                          Prospective observational   Manuscript         41 years (range: unknown)                  Severe TBI                                               Primary: to evaluate the relationship between CSF IL-6, IL-8, and IL-10 with TCD defined CBF
  Secondary: none mentioned                                                                                                                                                                                                                                                                                                                                                      
                                                                                                                                                                                                                                                                                                                                                                                 
  Stein et al. ([@B52])                                                                                                                           14 with CSF cytokines                                                       Prospective observational   Manuscript         31.6 years (range: unknown)                Severe TBI                                               Primary: to determine the relationship between CSF cytokines with ICP and patient outcome
  Secondary: none mentioned                                                                                                                                                                                                                                                                                                                                                      
                                                                                                                                                                                                                                                                                                                                                                                 
  **Nil association studies**                                                                                                                                                                                                                                                                                                                                                    
                                                                                                                                                                                                                                                                                                                                                                                 
  Amick et al. ([@B53])                                                                                                                           24                                                                          Prospective observational   Manuscript         5.4 years (range: 0.2--16 years)           Moderate--severe TBI                                     Primary: to determine the association between IL-2, IL-4, IL-6 and IL-12 with patient outcome
  Secondary: compare IL levels in CSF to non-TBI controls (*n* = 12)                                                                                                                                                                                                                                                                                                             
                                                                                                                                                                                                                                                                                                                                                                                 
  Buttram et al. ([@B54])                                                                                                                         36                                                                          Prospective observational   Manuscript         6.9 years (range: unknown)                 Severe TBI                                               Primary: to measure CSF cytokines and determine the impact of moderate hypothermia on expression. Also determine the link between CSF cytokines and outcome
  Secondary: compared CSF cytokine profile to non-TBI controls (*n* = 10)                                                                                                                                                                                                                                                                                                        
                                                                                                                                                                                                                                                                                                                                                                                 
  Csuka et al. ([@B55])                                                                                                                           28                                                                          Prospective observational   Manuscript         36 years (range: 16--67 years)             Severe TBI                                               Primary: to determine the association between various CSF and serum cytokines
  Secondary: to determine the association between CSF cytokines with outcome and ICP                                                                                                                                                                                                                                                                                             
                                                                                                                                                                                                                                                                                                                                                                                 
  Diamond et al. ([@B56])                                                                                                                         59 with CSF cytokines                                                       Prospective observational   Manuscript         Unclear mean age for CSF cytokine cohort   Moderate--severe TBI                                     Primary: to determine the association between serum and CSF cytokine levels with the development of PTE
  Secondary: to compare serum and CSF levels with healthy control values. Also assess genetic IL-1b associations with PTE                                                                                                                                                                                                                                                        
                                                                                                                                                                                                                                                                                                                                                                                 
  Goodman et al. ([@B57])                                                                                                                         23                                                                          Prospective observational   Manuscript         32.7 years (range: 15--57 years)           Severe TBI                                               Primary: to compare CSF and jugular venous cytokine profiles
  Secondary: to compare cytokine profiles to ICP and CPP                                                                                                                                                                                                                                                                                                                         
                                                                                                                                                                                                                                                                                                                                                                                 
  Gopcevic et al. ([@B58])                                                                                                                        20                                                                          Prospective observational   Manuscript         53 years (range: unknown)                  Severe TBI                                               Primary: to determine the association between jugular serum and CSF IL-8 levels with in-hospital mortality
  Secondary: to determine the association between jugular plasm and CSF IL-8 levels                                                                                                                                                                                                                                                                                              
                                                                                                                                                                                                                                                                                                                                                                                 
  Lenzlinger et al. ([@B59])                                                                                                                      41                                                                          Prospective observational   Manuscript         38 years (range: 15--74 years)             Severe TBI                                               Primary: to determine the association between CSF and serum cytokines with patient outcome
  Secondary: to compared serum and CSF cytokine profiles                                                                                                                                                                                                                                                                                                                         
                                                                                                                                                                                                                                                                                                                                                                                 
  Maier et al. ([@B60])                                                                                                                           29                                                                          Prospective observational   Manuscript         54.8 years (range: 16--85 years)           Severe TBI                                               Primary: to determine the CSF profile for two soluble tumor necrosis factor receptors (TNFR's)
  Secondary: to determine the association between CSF sTNFR levels and patient outcome                                                                                                                                                                                                                                                                                           
                                                                                                                                                                                                                                                                                                                                                                                 
  Maier et al. ([@B61])                                                                                                                           29                                                                          Prospective observational   Manuscript         45.5 years (range: 18--75 years)           Severe TBI                                               Primary: to evaluate the correlation between CSF and serum cytokine
  Secondary: to determine the association between cytokine profile and patient outcome. Also, compare to CSF from healthy volunteers (*n* = 35)                                                                                                                                                                                                                                  
                                                                                                                                                                                                                                                                                                                                                                                 
  Morganti-Kossmann et al. ([@B62])                                                                                                               42                                                                          Unclear                     Meeting abstract   Unknown                                    Severe TBI with various primary and secondary injuries   Primary: to determine the association between serum and CSF cytokines with injury patterns
  Secondary: to determine the association between cytokine profiles and patient outcome                                                                                                                                                                                                                                                                                          
                                                                                                                                                                                                                                                                                                                                                                                 
  Newell et al. ([@B63])                                                                                                                          66                                                                          Retrospective case series   Manuscript         6 years (range: 0.1--16 years)             Severe TBI                                               Primary: to measure inflammatory markers in the CSF linked to T-cell activation
  Secondary: to comment on the association between these markers and patient outcome. Also compare levels to healthy controls                                                                                                                                                                                                                                                    
                                                                                                                                                                                                                                                                                                                                                                                 
  Ross et al. ([@B64])                                                                                                                            50                                                                          Prospective observational   Manuscript         21 years (range: 4--70 years)              Severe TBI                                               Primary: to compare serum and CSF TNF-a in TBI patients to healthy controls (*n* = 46)
  Secondary: to compare TNF-a levels to patient outcome                                                                                                                                                                                                                                                                                                                          
                                                                                                                                                                                                                                                                                                                                                                                 
  Uzan et al. ([@B65])                                                                                                                            11                                                                          Prospective observational   Manuscript         28.5 years (range: 2.5--53 years)          Severe TBI                                               Primary: to determine the association between NO metabolic products and IL-8
  Secondary: to determine the association between NO and IL-8 with patient outcome                                                                                                                                                                                                                                                                                               

*TBI, traumatic brain injury; sTBI, severe TBI; RCT, randomized control trial; ICP, intracranial pressure; CPP, cerebral perfusion pressure; CSF, cerebrospinal fluid; CBF, cerebral blood flow; PbtO~2~, partial pressure of oxygen in brain tissue; TCD, transcranial Doppler; DC, decompressive craniectomy; IL, interleukin; a, alpha; b, beta; ra, receptor antagonist; TNF, tumor necrosis factor; NO, nitrous oxide; TNFR, tumor necrosis factor receptor; NGF, nerve growth factor; BDNF, brain-derived neurotrophic factor; GDNF, glial-derived neurotrophic factor; PTE, post-traumatic epilepsy; PTD, post-traumatic depression; PCA, principle component analysis*.

###### 

CMD cytokine measures and outcomes.

  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Reference                                                                                                                                                                                                                                                                                                                                                                                                         Catheter location and measured CMD cytokines                                                                                    Interventional therapies applied during measurement                                   Primary outcome                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      Secondary outcome                                                                                               Complications to CMD          Conclusions
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------ --------------------------------------------------------------------------------------------------------------- ----------------------------- ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Cederberg et al. ([@B11])                                                                                                                                                                                                                                                                                                                                                                                         Mixed locations                                                                                                                 Not specified                                                                         6/7 patients survived                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                N/A                                                                                                             Not specified                 IL-6/IL-8 are increase in CDM both in "healthy" and peri-lesional tissue

  IL-6/IL-8                                                                                                                                                                                                                                                                                                                                                                                                         IL-6 and IL-8 was increased in survivors                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 

  Unclear sampling interval \[3 samples in each patient over course of intensive care unit (ICU) stay\]                                                                                                                                                                                                                                                                                                             Peri-lesional location of CMD catheter yielded higher IL-6 and IL-8 levels                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               

  Perfusate not specified                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             

  Figaji et al. ([@B12])                                                                                                                                                                                                                                                                                                                                                                                            Unclear locations                                                                                                               Not specified                                                                         Variable individual cytokine responses                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               N/A                                                                                                             Not specified                 IL-6/IL-8 are consistently increased in CMD in pediatric sTBI

  IL-1a, IL-1b, IL1-ra, IL-6, IL-8, and IL-10; VEGF, and MCP-1                                                                                                                                                                                                                                                                                                                                                      IL-6 and IL-8 were the most consistently elevated across all patients                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    

  Unclear sampling interval                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  

  Perfusate not specified                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             

  Guilfoyle et al. ([@B13])                                                                                                                                                                                                                                                                                                                                                                                         2× CMD catheters per patients (1 healthy tissue, 1 peri-lesional)                                                               Not specified                                                                         IL-7 (*p* \< 0.05) and IL-8 (\<0.05) were found to be higher in peri-lesional tissue\                                                                                                                                                                                                                                                                                                                                                                                                                                                N/A                                                                                                             Not specified                 IL-7/IL-8 are higher in peri-lesional tissue\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          IL-1b and interferon gamma (INF-g) were higher in peri-lesional tissue within the first 72 h post-injury                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           IL-1b and INF-g are higher in peri-lesional tissue within the first 72 h

  "42 cytokines" IL-7 and IL-8                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               

  Unclear sampling interval                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  

  Perfusate not specified                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             

  [^a^](#tfn4){ref-type="table-fn"}Helmy et al. ([@B14])                                                                                                                                                                                                                                                                                                                                                            Area of "diffuse injury"                                                                                                        Not specified                                                                         IL-1b and TNF are covariate\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         N/A                                                                                                             Not specified                 PCA of CMD cytokine profiles yields covariate relationships between specific cytokines and temporal expression pattern
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          MIP-1a and MIP-1b were coexpressed\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          Earlier temporal expression of IL-6, GRO, G-CSF, IP10 compared to IL-10, MCP-3, IL-17                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              

  EGF, Eotaxin, FGF-2, fms-like tyrosine kinase 3 (Flt3) lig, Frac, G-CSF, GM-CSF, GRO, IFN-a2, IFN-g, IL-1a, IL-1b, IL-1ra, IL-2, IL-3, IL-4, IL-5, IL-6, IL-7, IL-8, IL-9, IL-10, IL-12p40, IL-12p70, IL-13, IL-15, IL-17, inducible protein (IP)-10, MCP-1, MCP-3, MDC, MIP-1a, MIP-1b, PDGF-AA, PDGF-AAAB, regulated on activation, normal T cell expressed and secreted (RANTES), sCD40L, sIL-2R, TGF-a, TNF   IL-1ra and IL-1a are covariate\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          
                                                                                                                                                                                                                                                                                                                                                                                                                    MIP-1a and MIP-1b were coexpressed\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      
                                                                                                                                                                                                                                                                                                                                                                                                                    Earlier temporal expression of IL-6, GRO, G-CSF, IP10 compared to IL-10, MCP-3, IL-17                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    

  q6 h pooled sampling over 5 days                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           

  3.5% human ablumin solution perfusate                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             

  [^a^](#tfn4){ref-type="table-fn"}Helmy et al. ([@B15])                                                                                                                                                                                                                                                                                                                                                            Double side-by-side in six patients (to analyze perfusate), and single catheter in six patients---unclear tissue location       Unclear; two patients under went DC for refractory ICP                                Albumin perfusate led to significantly higher fluid recovery compared to crystalloid. Albumin perfusate led to significantly higher cytokine recovery (18 cyotkines)Brain concentrations of 23 cytokines were significantly higher than jugular plasma concentrations (ex. IL-1ra, IL-1a, IL-1b, IL-6, IL-8, IL-10, IL-12p70, MCP-1) Many cytokines displayed a temporal expression, with expression within the first 72 h (e.g., TNF, IL-7, IL-8, MIP1a, sCD40L, IL-1β, GRO, PDGF, AA, RANTES, MIP-1b, IL-1ra, G-CSF, IP10, IL-6)   N/A                                                                                                             Not specified                 Ablumin CMD perfusate led to increased fluid and cytokine recoveryBrain cytokine concentrations were significantly higher than jugular plasma for 23 cytokines. Many cytokines displayed a temporal expression patter with early expression post-injury (72 h)

  EGF, Eotaxin, FGF-2, Flt3 lig, Frac, G-CSF, GM-CSF, GRO, IFN-a2, IFN-g, IL-1a, IL-1b, IL-1ra, IL-2, IL-3, IL-4, IL-5, IL-6, IL-7, IL-8, IL-9, IL-10, IL-12p40, IL-12p70, IL-13, IL-15, IL-17, IP-10, MCP-1, MCP-3, MDC, MIP-1a, MIP-1b, PDGF-AA, PDGF-AAAB, RANTES, sCD40L, sIL2R, TGFa, TNF                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               

  q6 h pooled sampling over 5 days                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           

  Assessed both crystalloid and 3.5% human albumin perfusate                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             

  [^b^](#tfn5){ref-type="table-fn"}Helmy et al. ([@B16])                                                                                                                                                                                                                                                                                                                                                            Right frontal location (in setting of diffuse injury)\                                                                          Group 1 (*n* = 10): after baseline 6 h CMD samples; received 100 mg rhIL-1ra subcut   No complications secondary to rhIL-1ra were seen.CMD IL-1ra concentrations were significantly higher in the treatment group vs. control (*p* = 0.02), with variation over time (*p* \< 0.0001)MDC was significantly lower in the rhIL-1ra (*p* = 0.05)                                                                                                                                                                                                                                                                               N/A                                                                                                             Not specified                 rhIL-1ra appears safe in severe diffuse TBIrhIL-1ra reaches the brain extracellular fluidMDC was lower in the rhIL-1ra group
                                                                                                                                                                                                                                                                                                                                                                                                                    42 cytokine array\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       
                                                                                                                                                                                                                                                                                                                                                                                                                    q6 h pooled sampling for 5 days\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         
                                                                                                                                                                                                                                                                                                                                                                                                                    Isotonic central nervous system perfusate                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                

  Repeated q24 h for total of five doses                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     

  Group 2 (*n* = 10): control group                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          

  No specifics on other ICU therapies                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             

  [^b^](#tfn5){ref-type="table-fn"}Helmy et al. ([@B17])                                                                                                                                                                                                                                                                                                                                                            Right frontal location (in setting of diffuse injury)\                                                                          Group 1 (*n* = 10): after baseline 6 h CMD samples; received 100 mg rhIL-1ra subcut   Based on PCA it was found that cytokines associated with macrophage recruitment were decreased in the rhIL-1ra group (MIP-1a, MCP-3, Fractalkine, GM-CSF)                                                                                                                                                                                                                                                                                                                                                                            N/A                                                                                                             Not specified                 CMD macrophage base cytokines are decreased in rhIL-1ra-treated patients
                                                                                                                                                                                                                                                                                                                                                                                                                    42 cytokine array\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       
                                                                                                                                                                                                                                                                                                                                                                                                                    q6 h pooled sampling for 5 days\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         
                                                                                                                                                                                                                                                                                                                                                                                                                    3.5% human albumin perfusate                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             

  Repeated q24 h for total of five doses                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     

  Group 2 (*n* = 10): control group                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          

  No specifics on other ICU therapies                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             

  Hillman et al. ([@B18])                                                                                                                                                                                                                                                                                                                                                                                           Paired CMD catheter placement in peri-lesional tissue                                                                           Not specified                                                                         CMD IL-6 concentrations varied depending on underlying condition and secondary injury (i.e., ischemia)                                                                                                                                                                                                                                                                                                                                                                                                                               N/A                                                                                                             1 catheter membrane failure   CMD IL-6 concentrations varied from patient to patient and depending on initial and secondary injury patterns

  IL-6                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       

  q6 h pooled analysis                                                                                                                                                                                                                                                                                                                                                                                              The temporal expression of CMD measured IL-6 varied between patients                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     

  Ringer's/dextran 60 or human albumin perfusate                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             

  Hillman et al. ([@B19])                                                                                                                                                                                                                                                                                                                                                                                           Peri-lesional tissue\                                                                                                           Not specified                                                                         CMD biochemical evidence of ischemia (LPR \> 30 and glutamate \>80 μmol/L for 24 h period) was associated with significant IL-6 increase (*p* \< 0.01), which subsided after \~90 h post-injury (*p* \< 0.001)                                                                                                                                                                                                                                                                                                                       N/A                                                                                                             Not specified                 CMD IL-6 displays a correlation with CMD biochemical ischemia and a temporal correlation post-injury (in the absence of biochemical ischemia)
                                                                                                                                                                                                                                                                                                                                                                                                                    IL-1b, IL-6\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             
                                                                                                                                                                                                                                                                                                                                                                                                                    q6 h pooled analysis\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    
                                                                                                                                                                                                                                                                                                                                                                                                                    3.5% human albumin perfusate                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             

  In those patients without biochemical ischemia, IL-6 levels spiked in the first 48 h (*p* \< 0.01)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         

  IL-1b activation was less commonly observed (only 53% of measures)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             

  Hutchinson et al. ([@B20])                                                                                                                                                                                                                                                                                                                                                                                        Unclear tissue location ("frontal cortex")\                                                                                     Not specified                                                                         IL-1a and IL-1b concentrations were lower than IL-1ra\                                                                                                                                                                                                                                                                                                                                                                                                                                                                               ICP: ICP was negatively correlation to IL-1ra (*p* = 0.041)                                                     Not specified                 The appears to be a correlation between IL-1ra and IL-1bThere is a negative correlation between ICP and IL-1raMean IL-1ra levels correlate to patient outcome at 6 months
                                                                                                                                                                                                                                                                                                                                                                                                                    IL-1a, IL-1b, IL-1ra\                                                                                                                                                                                                 A positive correlation between IL-1ra and IL-1b was seen (*p* = 0.028)\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            
                                                                                                                                                                                                                                                                                                                                                                                                                    q6 h pooled samples (mean no. samples = 9.1; range = 4--23)\                                                                                                                                                          No correlation between IL-1b and IL-1ra was found\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 
                                                                                                                                                                                                                                                                                                                                                                                                                    Isotonic central nervous system perfusate                                                                                                                                                                             No correlation between cytokines and CMD glucose, glutamate, LPR                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   

  No correlation between other cytokines and ICP                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             

  No correlation between cytokines and CPP                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   

  Outcome: significant relationship between mean IL-1ra levels and poor outcome (dichotomized GOS at 6 months) (*p* = 0.018)---high IL-1ra was associated with good outcome                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  

  No relationship between IL-1a and IL-1b with outcome                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             

  Mellergard et al. ([@B21])                                                                                                                                                                                                                                                                                                                                                                                        Mixed locations; some patients with two catheters (unclear which patients)                                                      Not specified                                                                         IL-1b peaked in the first 12 h period\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               N/A                                                                                                             Not specified                 CMD catheter insertion leads to IL-1b/IL-6/IL-8/MIP1b within the first 6--12 h, which then decrease during the subsequent time afterward
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          IL-6 peaked after 12 h post-insertion\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          IL-8 peaked within the first 6 h post-insertion\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          MIP-1b peaked within the first 6 h post-insertion\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          FGF-2 peaked within the first 6 h post-insertion\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          IL-10, VEGF, and RANTES did not show a temporal profile                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            

  IL-1b, IL-6, IL-8, FGF-2, MIP-1b, RANTES, VEGF, IL-10                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      

  q6 h pooled samples for 36 h                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               

  Ringer-dextran 60 perfusate                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             

  [^c^](#tfn6){ref-type="table-fn"}Mellergard et al. ([@B22])                                                                                                                                                                                                                                                                                                                                                       Paired catheters (1 peri-lesonal; 1 healthy tissue)---used the catheter with highest glycerol levels for measuring cytokines\   Not specified; various surgical procedure for hemotomas in TBI group                  IL-1b increased during the first 48 h, and then decreased\                                                                                                                                                                                                                                                                                                                                                                                                                                                                           N/A                                                                                                             Not specified                 IL-1b and IL-6 display a peak elevation during the first 48 h post-TBI\
                                                                                                                                                                                                                                                                                                                                                                                                                    IL-1b, IL-6, IL-10\                                                                                                                                                                                                   IL-6 increased over the first 48 h, and then decreased\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            IL-10 remains elevated through the first 7 days post-TBI
                                                                                                                                                                                                                                                                                                                                                                                                                    q6 h pooled analysis for 7 days\                                                                                                                                                                                      IL-10 remained elevated throughout the measurement period                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          
                                                                                                                                                                                                                                                                                                                                                                                                                    Ringer-dextran 60 perfusate                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             

  [^c^](#tfn6){ref-type="table-fn"}Mellergard et al. ([@B23])                                                                                                                                                                                                                                                                                                                                                       Paired catheters (1 peri-lesonal; 1 healthy tissue)---used the catheter with highest glycerol levels for measuring cytokines    Not specified; various surgical procedure for hemotomas in TBI group                  FGF-2 levels peaked at day 3 post-TBI\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               N/A                                                                                                             Not specified                 FGF-2/VEGF levels peaked on days 3 and 2 post-TBI
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          VEGF levels peaked on day 2 post-TBI                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               

  FGF-2, VEGF                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                

  q6 h pooled analysis for 7 days                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            

  Ringer-dextran 60 perfusate                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             

  Mellergard et al. ([@B24])                                                                                                                                                                                                                                                                                                                                                                                        Unclear location\                                                                                                               Local protocols; not otherwise specified                                              IL-1b, IL-8, and IL-10 did not display age-related differences                                                                                                                                                                                                                                                                                                                                                                                                                                                                       N/A                                                                                                             Not specified                 There may be an age-related difference in the expression of VEGF, MIP-1b, RANTES, and FGF-2 post-TBI
                                                                                                                                                                                                                                                                                                                                                                                                                    IL-1b, IL-6, IL-8, FGF-2, MIP-1b, RANTES, VEGF, IL-10\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   
                                                                                                                                                                                                                                                                                                                                                                                                                    q6 h pooled sample analysis\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             
                                                                                                                                                                                                                                                                                                                                                                                                                    Ringer-dextran 60 perfusate                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              

  VEGF, MIP-1b, and RANTES were different in the \<25 years age group vs. over 25 years age                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  

  FGF-2 levels were significantly higher in the \>65-year-old group (*p* \< 0.0001)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             

  Mondello et al. ([@B25])                                                                                                                                                                                                                                                                                                                                                                                          Unclear location\                                                                                                               Not specified                                                                         IL-6 showed high initial values that then decreased, in contrast IL-1beta, TNF-alpha and INF-gamma showed later elevations                                                                                                                                                                                                                                                                                                                                                                                                           N/A                                                                                                             Not specified                 Variable cytokine temporal profiles are seen post-TBI
                                                                                                                                                                                                                                                                                                                                                                                                                    IL-1b, IL-6, TNF-a, INF-g\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               
                                                                                                                                                                                                                                                                                                                                                                                                                    Unclear sampling interval\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               
                                                                                                                                                                                                                                                                                                                                                                                                                    Unclear perfusate                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        

  UCH-L1 levels negatively correlated (*p* \< 0.05) with IL-1beta, widely used biomarker of inflammation                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             

  Parez-Barcena et al. ([@B26])                                                                                                                                                                                                                                                                                                                                                                                     Right frontal location; unclear tissue quality\                                                                                 Varied ICP/CPP directed therapies; some use of barbiturates                           IL-1b, IL-6, and IL-8 peaked during first 24 h post-injury\                                                                                                                                                                                                                                                                                                                                                                                                                                                                          ICP: no correlation between IL-1b, IL-6, IL-8 and IL-10 with ICP                                                Not specified                 IL-1b, IL-6 and IL-8 peaked within the first 24 h post-injuryNo clear association was found between cytokines and ICP, PbtO~2~, CT changes
                                                                                                                                                                                                                                                                                                                                                                                                                    IL-1b, IL-6, IL-8, IL10, IL-12, TNF-a\                                                                                                                                                                                IL-10 remained unchanged during the sampling period                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                
                                                                                                                                                                                                                                                                                                                                                                                                                    q8 h sample analysis (up to 248 h duration)\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             
                                                                                                                                                                                                                                                                                                                                                                                                                    Isotonic central nervous system perfusate                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                

  PbtO~2~: no clear correlation between cytokines and PbtO~2~\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               
  CT: no association found between cytokines and subsequent CT defined swelling or lesion change                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             

  Roberts et al. ([@B27])                                                                                                                                                                                                                                                                                                                                                                                           Healthy tissue\                                                                                                                 Varied; one patient had DC                                                            IL-1a, IL-1b, and TNF-a were elevated initially after injury\                                                                                                                                                                                                                                                                                                                                                                                                                                                                        Neuro Exam: IL-1b, IL-4 and TNF-a levels were substantially higher in those with loss of pupillary reactivity   Not specified                 IL-1a, IL-1b, TNF-a, IL-6 and IL-8 predominate the cytokine response post TBIVarious patterns of MMP changes are seen in correlation with changes in cytokine expressionIL-1b, IL-4 and TNF-a levels were higher in those with loss of pupillary reactivityIL-6 and IL-8 correlation with CPP. TNF-a correlations with ICP
                                                                                                                                                                                                                                                                                                                                                                                                                    IL-1a, IL-1b, IL-2, IL-4, IL-5, IL-6, IL-8, IL-10, and TNF-a\                                                                                                                                                         IL-6 and IL-8 were substantially higher in the CMD compared to other cytokines\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    
                                                                                                                                                                                                                                                                                                                                                                                                                    q6 h pooled analysis (up to 156 h of monitoring)\                                                                                                                                                                     IL-5 was barely detectable\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        
                                                                                                                                                                                                                                                                                                                                                                                                                    Isotonic central nervous system perfusate                                                                                                                                                                             Similar cytokine concentrations were seen in CSF and CMD, which were both substantially higher than jugular plasma sampled\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          Increase CMD concentrations of MMP-8 and MMP-9 were seen with increases in the levels of IL-1a, IL-2, and IL-1a and -2 and TNF-a, respectively. In contrast, the CMD levels of MMP-7 decreased with increases in IL-1b, IL-2, and IL-6                                                                                                                                                                                                                                                                                                                                                                                                                                             

  ICP: IL-2 displayed a negative correlation to ICP                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          

  TNF-a displayed a negative correlation to ICP                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              

  CPP: IL-6 and IL-8 displayed a negative correlation to CPP                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 

  PbtO~2~: no correlation found between cytokines and PbtO~2~                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                

  Outcome: n*o* correlation between cytokines and GOS                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             

  Winter et al. ([@B28])                                                                                                                                                                                                                                                                                                                                                                                            Peri-lesional\                                                                                                                  Not specified                                                                         CMD cytokine analysis is feasible and safe                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           Peak cytokine levels were seen within the first 36 h post-injury                                                None                          CMD cytokine analysis is feasibleIL-1b may be the predominant CMD cytokine expressedUnclear patterns in survivors vs. non-survivors
                                                                                                                                                                                                                                                                                                                                                                                                                    IL-1b, IL-6, NGF\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        
                                                                                                                                                                                                                                                                                                                                                                                                                    q3 h sampling (for 6 days)\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              
                                                                                                                                                                                                                                                                                                                                                                                                                    Normal saline perfusate                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  

  IL-1b predominated with substantially higher concentrations compared to IL-6 and NGF                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       

  IL-6 was high in survivors, while NGF was lower in non-survivors                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             

  Winter et al. ([@B29])                                                                                                                                                                                                                                                                                                                                                                                            Healthy tissue                                                                                                                  Not specified                                                                         Higher IL-6 was seen in survivors (*p* = 0.04)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       N/A                                                                                                             None                          IL-6 levels in CMD samples may correlation to survival and GOS at 6 months

  IL-1b, IL-6, NGF                                                                                                                                                                                                                                                                                                                                                                                                  Peak IL-6 correlated to GOS at 6 months (*p* = 0.03)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     

  q3 h sampling                                                                                                                                                                                                                                                                                                                                                                                                     Peak NGF:IL-1b ratios were significantly lower in survivors (*p* = 0.01)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 

  Normal saline perfusate                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    
  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

*TBI, traumatic brain injury; sTBI, severe TBI; GOS, Glasgow outcome scale; CMD, cerebral microdialysis; RCT, randomized control trial; ICP, intracranial pressure; CT, computed tomography; PbtO~2~, brain tissue oxygen monitoring; CPP, cerebral perfusion pressure; CSF, cerebrospinal fluid; LPR, lactate:pyruvate ratio; DC, decompressive craniectomy; μmol, micromolar; mm Hg, millimeters of mercury; L, liter; μmol, micromolar; IL, interleukin; a, alpha; b, beta; g, gamma; TNF, tumor necrosis factor; INF, interferon; MCP, monocyte chemoattractant protein; MIPs, macrophage inflammatory proteins; TGF, transforming growth factor; NGF, nerve growth factor; BDNF, brain-derived neurotrophic factor; GDNF, glial-derived neurotrophic factor; TNFR, tumor necrosis factor receptor; GM-CSF, granulocyte macrophage colony stimulating factor; sVCAM, soluble vascular cell adhesion molecule; sICAM, soluble intracellular adhesion molecule; PDGF, platelet-derived growth factor; VEGF, vascular endothelial growth factor; MDC, macrophage-derived chemokine; FGFR, fibroblast growth factor receptor*.

*^a^Same patient population reported in both Helmy et al. ([@B14]) and Helmy et al. ([@B15])*.

*^b^Same patient population described in Helmy et al. ([@B16]) and Helmy et al. ([@B17])*.

*^c^Same patient population reported in both Mellergard et al. ([@B22]) and Mellergard et al. ([@B23])*.

###### 

CSF cytokine measures and outcomes.

  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Reference                                                                                                                                                                                                                    Interval of cytokine measure                                                                        Measured CMD cytokines                                                                                                                Interventional therapies applied during measurement                                             Outcome(s) of interest (patient outcome, neurophysiologic outcome, tissue outcome)                                                                                      Other outcomes                                                                                                                                                                                                                                                                                        Conclusions
  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- --------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------------------- ----------------------------------------------------------------------------------------------- ----------------------------------------------------------------------------------------------------------------------------------------------------------------------- ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Abboud et al. ([@B30])                                                                                                                                                                                                       q12-h Intervals for 5 days                                                                          IL-1α,IL-1β, IL-2, IL-4, IL-5, IL-6, IL-8, IL-10, IL-13, MIP-1a, MIP-1b, TNF-a, VEGF                                                  Not specified                                                                                   GOS at 6 and 12 months post-injury\                                                                                                                                     N/A                                                                                                                                                                                                                                                                                                   Elevated IL-4, IL-6, IL-8, IL-23, and TNF-a levels may be associated with poor outcome at 6 and 12 months
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         Statistically significant differences in IL-4, IL-5, IL-6, IL-8, IL-13, and TNF-α (all *p* \< 0.05) were observed between TBI survivors vs. non-survivors over 5 days                                                                                                                                                                                                                                                                                                         

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 Similarly, low IL-5 and IL-13 may be associated with poor outcome                                                                                                                                                                                                                                     

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       

  Bell et al. ([@B31])                                                                                                                                                                                                         q24-h Intervals for 3 days                                                                          IL-6, IL-10                                                                                                                           High variable; barbiturates and various ICP/CPP-directed therapies                              Mortality (at unclear interval)                                                                                                                                         IL-6 and IL-10 levels were increased compared to controls                                                                                                                                                                                                                                             Elevated IL-10 levels may be associated with mortality

  IL-6 is not associated with mortality                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                

  Control group had banked CSF                                                                                                                                                                                                 IL-10 is associated with mortality (*p* = 0.022)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       

  Chiaretti et al. ([@B32])                                                                                                                                                                                                    At 2 and 48 h post-injury\                                                                          IL-6, NGF                                                                                                                             Highly protocolized therapy; seemingly homogenous between patients                              GOS at 6 months                                                                                                                                                         IL-6 and NGF were both elevated and increased between the two sampling periods                                                                                                                                                                                                                        Lower IL-6 and NGF levels early post-TBI may be associated with better outcome at 6 months
                                                                                                                                                                                                                               Controls were initially investigated for meningitis but were found to be negative. CSF was banked                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       

  Low IL-6 and NGF at 2 h post-injury was associated with good outcome (*p* \< 0.01)\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  
  Increased IL-6 variation between the two time points was correlated with better outcome                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              

  IL-6 and NGF were positively correlated at both time periods                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       

  Chiaretti et al. ([@B33])                                                                                                                                                                                                    At 2 and 48 h post-injury                                                                           IL-1b, IL-6, NGF, BDNF, GDNF                                                                                                          Highly protocolized therapy; seemingly homogenous between patients                              GOS at 6 months\                                                                                                                                                        N/A                                                                                                                                                                                                                                                                                                   Low initial NGF, followed by increased NGF/IL-6 may be associated with good outcome at 6 months
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         Low NGF at 2 h (*p* \< 0.01) and high NGF/IL-6 (*p* = 0.02/*p* \< 0.01) at 48 h were associated with better outcome                                                                                                                                                                                                                                                                                                                                                           

  Low IL-1b at 48 h may be associated with better outcome at 6 months                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  

  Low IL-1b at 48 h was associated with better outcome (*p* \< 0.01)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       

  Chiaretti et al. ([@B34])                                                                                                                                                                                                    At 2 and 24 h post-injury                                                                           IL-1b and IL-6                                                                                                                        Highly protocolized therapy; seemingly homogenous between patients                              Dichotomized GOS at 6 months (good = 4 or 5; poor = 3 or less)                                                                                                          IL-1b and IL-6 at 2 h were higher in the TBI cohort                                                                                                                                                                                                                                                   Elevated IL-1b and IL-6 at both 2 and 24 h post-injury may be associate with poor outcome at 6 months

  Higher CSF IL-1b and IL-6 at both 2 h and 24 h were seen in those patients with poor outcome at 6 months                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       

  Hans et al. ([@B35])                                                                                                                                                                                                         Daily CSF samples up to 21 days post-injury                                                         IL-6 and sIL-6R                                                                                                                       Not specified                                                                                   Dichotomized GOS at 6 months (good = 4 or 5; poor = 3 or less)                                                                                                          CSF levels of IL-6 and sIL-6R were higher than compared to plasma                                                                                                                                                                                                                                     Elevated IL-6/sIL-6R may be associated with poor outcome at 6 months

  High IL6/sIL-6R was associated with poor outcome at 6 months                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       

  Hayakata et al. ([@B36])                                                                                                                                                                                                     6, 12, 24, 48, 72, and 96 h after injury                                                            TNF-a, IL-1, IL-6, IL-8, and IL-10                                                                                                    Varied therapies; hypothermia and other ICP/CPP-directed approaches                             Dichotomized GOS at 6 months (good = 4 or 5; poor = 3 or less)\                                                                                                         ICP: IL-1b was significantly positively correlated with ICP throughout the entire study (*p* \< 0.05)\                                                                                                                                                                                                Elevated IL-1b may be associated with poor outcome at 6 monthsElevated IL-1b may be associated with elevated ICP
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         CSF IL-1b was found to be higher in those with poor outcome                                                                                                             Various cytokine elevations were seen during S100B elevations. IL-1b peaks was correlated with S100B peak (*p* \< 0.005)                                                                                                                                                                              

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       

  Jamil et al. ([@B37])                                                                                                                                                                                                        Unclear interval; "acute" period post-TBI                                                           IL-1b, IL-4, IL-5, IL-6, IL-7, IL-8, IL-10, IL-12, TNF-a, sICAM-1, sVCAM-1, sFAS                                                      Not specified                                                                                   Patient health questionnaire (PHQ-9) at 6 and 12 months post-injury                                                                                                     N/A                                                                                                                                                                                                                                                                                                   Elevated IL-6 and IL-8 may be associate with depression at 6TNF-a, IL-4, and IL-1b may be associated with lower chance of depression at 12 months

  Acute CSF IL-6 (*p* = 0.008), IL-8 (*p* = 0.034), and ICAM1 (*p* = 0.025) levels were higher among patients who would go on to develop depression 6 months after injury                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              

  Acute CSF TNF-a (*p* = 0.036), IL-4 (*p* = 0.007), and IL-1b (*p* = 0.001) levels were individually associated with lower depression risk at 12 months post-injury                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       

  Juengst et al. ([@B38])                                                                                                                                                                                                      Within first week of injury                                                                         IL-4, IL-5, IL-8, IL-12, TNF-a, sVCAM, sICAM                                                                                          Not specified                                                                                   Apathy subscale of the frontal systems behavior scale, collected at 6 and 12 months post-TBI                                                                            N/A                                                                                                                                                                                                                                                                                                   Higher acute CSF IL5, sVCAM, and sICAM with apathy at 6 months and lower acute serum TNFalpha, IL8, and IL5 with apathy at 12 months

  Higher acute CSF IL5, sVCAM, and sICAM with apathy at 6 months and lower acute serum TNFalpha, IL8, and IL5 with apathy at 12 months (*p* \< 0.05)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       

  Juengst et al. ([@B39])                                                                                                                                                                                                      2 times daily for 6 days                                                                            TNF-a                                                                                                                                 Not specified                                                                                   At 6 and 12 months post-injury, FrSBe disinhibition subscale; suicidal endorsement was assessed by the PHQ-9                                                            TBI patients had significantly higher CSF TNF-a levels compared to controls                                                                                                                                                                                                                           Acute levels of TNF-a may correlate to 6 and 12 month rates of disinhibition

  No relationship between TNF-a in CSF and suicidality at 6 or 12 months                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               

  Acute serum TNFa levels were inversely associated with 12-month disinhibition (*r* = 0.520, *p* = 0.027) and achieved borderline significance with 6-month disinhibition (*r* = 0.470, *p* = 0.057)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       

  Juengst et al. ([@B40])                                                                                                                                                                                                      2 times daily up to 6 days                                                                          IL-1β, IL-4, IL-5, IL-6, IL-7, IL-8, IL-10, IL-12, TNF-a, sVCAM-1, sICAM-1, sFAS                                                      Not specified                                                                                   PHQ-9 was administered to participants at 6 and 12 months after injury                                                                                                  IL-1β, IL-4, IL-6, IL-7, IL-8, IL-10, TNF-α, sVCAM-1, sICAM-1, and sFAS (*p* \< 0.05) were significantly elevated compared to controls                                                                                                                                                                Elevated sVCAM-1, sICAM-1 and sFAS may be associated with PTD at 6 monthsElevated IL-7 and IL-8 may be associated with PTD at 12 months

  The inflammatory cell surface markers sVCAM-1, sICAM-1, and sFAS in the CSF were each positively associated with PTD at 6 months (*p* \< 0.02 for all comparisons).                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  

  The cytokine IL-8 was positively associated with PTD at 12 months (*p* \< 0.02), while the cytokine IL-7 was inversely associated with PTD at 12 months (*p* \< 0.05)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       

  Kirchhoff et al. ([@B41])                                                                                                                                                                                                    Upon EVD insertion, then at 12, 24, and 48 h post-injury                                            IL-10                                                                                                                                 Not specified                                                                                   Mortality at unspecified interval\                                                                                                                                      IL-10 was higher at all time points compared to non-TBI controls                                                                                                                                                                                                                                      Elevated CSF IL-10 at admission was associated with mortality
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         IL-10 was significantly higher in non-survivors                                                                                                                                                                                                                                                                                                                                                                                                                               

                                                                                                                                                                                                                               Control group: CSF gained from spinal anesthetics in elective non-TBI surgical cases                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       

  Kossmann et al. ([@B42])                                                                                                                                                                                                     q24 h for unclear duration\                                                                         IL1b, IL-6, TNF-a, NGF                                                                                                                Various therapies; heterogeneous across population                                              Dichotomized GOS at 3 months (good = 4 or 5; poor = 3 or less)                                                                                                          IL-6 and NGF were high in TBI patients compared to control samples                                                                                                                                                                                                                                    NGF may be elevated in those with good outcome
                                                                                                                                                                                                                               Control group: non-TBI patients (1 VPS and 2 Dx LP)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     

  High IL-6 levels were associated with NGF presence in CSF                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            

  NGF levels were elevated in those with better outcomes                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       

  Kumar et al. ([@B43])                                                                                                                                                                                                        2 times daily for 5 days                                                                            IL-6                                                                                                                                  Not specified                                                                                   Dichotomized GOS at 6 and 12 months (good = 4 or 5; poor = 3 or less)                                                                                                   IL-6 levels were higher in TBI compared to controls                                                                                                                                                                                                                                                   High IL-6 during the first 5 days of injury may be associated with poor outcome at 6 months

  Association between high IL-6 upon admission and 6-month GOS (*p* = 0.003)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       

  Kumar et al. ([@B44])                                                                                                                                                                                                        2 times daily for up to 5 days                                                                      IL-1β, IL-4, IL-5, IL-6, IL-7, IL-8, IL-10, IL-12, TNF-a, sVCAM-1, sICAM-1, sFAS                                                      Not specified                                                                                   Trichotomized GOS at 6 and 12 months (good = 4 or 5; poor = 3 or 2; dead = 1)                                                                                           Cytokines were elevated in TBI patients compared to controls                                                                                                                                                                                                                                          Elevated IL-5, IL-6, IL-8, IL-10, sVCAM-1, and sICMA-1 may be associated with poor outcome at 6 months

  Individuals in cluster 1 (increased sICAM-1, sFAS, IL-10, IL-6, sVCAM-1, IL-5, and IL-8) had a 10.9 times increased likelihood of GOS scores of 2/3 vs. 4/5 at 6 months compared to cluster 2 (increased IL-12, IL7, IL-4)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       

  Kushi et al. ([@B45])                                                                                                                                                                                                        Admission, 24, 72, and 168 h post-injury                                                            IL-6, IL-8                                                                                                                            High protocolized treatment; fairly homogeneous therapy                                         Mortality at unspecified interval                                                                                                                                       N/A                                                                                                                                                                                                                                                                                                   Elevated IL-6 and IL-8 during the first week post-TBI may be associated with mortality

  IL-6 and IL-8 levels were significantly higher in CSF compared to serum                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              

  IL-6 and IL-8 levels were significantly higher in non-survivors                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       

  Nwachuku et al. ([@B46])                                                                                                                                                                                                     q6 h for 5 days                                                                                     IL-1b, IL-6, TNF-a, IFN-a, IL-12p70, IL-10, and IL-8                                                                                  Not specified                                                                                   Dichotomized GOS at 3, 6, 12, and 24 months (good = 4 or 5; poor = 3 or less)                                                                                           N/A                                                                                                                                                                                                                                                                                                   Elevated mean 5-day levels of various cytokines may be associated with poor outcome at 3, 6, 12, and 24 months post-injury

  Mean 5-day levels of IFN-a, IL-10, IL-12 p70, IL-1, IL-6, IL-8, and TNF-a were associated with outcome (*p* \< 0.05)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       

  Santarseiri et al. ([@B47])                                                                                                                                                                                                  2 times daily for up to 6 days                                                                      IL-1β, IL-4, IL-5, IL-6, IL-7, IL-8, IL-10, IL-12, TNF-a, sVCAM-1, sICAM-1, sFAS                                                      Not specified                                                                                   Dichotomized GOS at 6 months (good = 4 or 5; poor = 3 or less)                                                                                                          N/A                                                                                                                                                                                                                                                                                                   Low mean IL-6, IL-8, IL-10, sICAM-1, and TNF-a may be associated with good outcome at 6 months post-injury

  Cortisol: high cortisol patients were more likely to have elevated IL-10, IL-1b, IL-6, sFas, sICAM-1, sVCAM-1 and TNFa (*p* \< 0.01 all comparisons, except IL-1b, *p* \< 0.05) compared to low cortisol patients                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    

  Outcome: significant associations between GOS and mean levels of IL-10, IL-6, IL-8, sFas, sICAM-1 (*p* \< 0.01) and TNF-a (*p* \< 0.05), with lower levels associated with favorable outcome                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       

  Shiozaki et al. ([@B48])                                                                                                                                                                                                     q6 h for unclear duration                                                                           IL-1b, IL-1ra, IL10, TNF-a, sTNFr-I                                                                                                   Highly Protocolized therapy                                                                     Dichotomized GOS at 6 months (good = 4 or 5; poor = 3 or less)                                                                                                          IL-1b, IL-1ra, sTNFr-I, and IL-10 were significantly higher in patients with high ICP than those with low ICP (*p* = 0.002, *p* = 0.006, *p* = 0.009, and *p* = 0.009, respectively). However, the CSF concentrations of TNF-a did not differ between patients with high ICP and those with low ICP   Elevated IL-lb, IL-1ra, IL-10, and sTNFr-I may be associated with poor outcome at 6 monthsElevated IL-1b, IL-1ra, IL-10, sTNFr-I may be associated with high ICP

  IL-1b, IL-1ra, sTNFr-I, and IL-10 were significantly higher in patients with an unfavorable outcome than in patients with a favorable outcome (*p* = 0.006, *p* = 0.009, *p* = 0.003, and *p* = 0.012, respectively)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 

  Singhal et al. ([@B49])                                                                                                                                                                                                      Unclear interval                                                                                    IL-1b, IL-6                                                                                                                           Not specified                                                                                   *SSEP: positive* correlation between IL-6 and SSEP96 (mean change in SSEP over 96 h) (*p* = 0.0133)                                                                     N/A                                                                                                                                                                                                                                                                                                   Elevated IL-6 may be positively correlated to SSEP over the first 96 hPeak IL-6 levels may be associated with outcome at 3 months

  Outcome: GOS at 3 months                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             

  Peak IL-6 levels were associated with good outcome (*p* = 0.026)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       

  Whalen et al. ([@B50])                                                                                                                                                                                                       Unclear sampling intervals                                                                          IL-8                                                                                                                                  Not specified                                                                                   Mortality at unspecified interval                                                                                                                                       IL-8 levels were elevated compared to controls                                                                                                                                                                                                                                                        Elevated IL-8 levels during the first week of injury may be associated with mortality

  Elevated CSF IL-8 levels were associated with mortality (*p* = 0.01)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 

  **Neurophysiologic association**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       

  Muller et al. ([@B51])                                                                                                                                                                                                       Daily for 7 days                                                                                    IL-6, IL-8, IL-10                                                                                                                     Not specified                                                                                   Transcranial doppler (TCD)-defined cerebral blood flow velocity                                                                                                         N/A                                                                                                                                                                                                                                                                                                   Elevated IL-6 and IL-8 in the first 7 days may be negatively correlated to TCD defined MCBFV

  Mean IL-6 and IL-8 level were significantly correlated to MCBFV (*r* = −0.341 and −0.361, respectively; *p* \< 0.05)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       

  Stein et al. ([@B52])                                                                                                                                                                                                        2 times daily for 7 days                                                                            IL-1b, IL-6, IL-8, IL-10, and TNF-a                                                                                                   High protocolized therapy                                                                       ICP: negative association between early (within first 12 h of injury) IL-6 and ICP (*p* = 0.004)                                                                        N/A                                                                                                                                                                                                                                                                                                   Elevated IL-6 within the first 12 h of injury may be associated with low ICPElevated IL-8 levels may be associated with low CPP

  Positive correlation between time spent with CPP below 60 mm Hg and IL-8 levels (*p* = 0.001)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        

  Outcome: dichotomized GOSE at 6 months (good = 5--8; poor = 1--4)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    

  No association between CSF cytokines and outcome                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     

  **Nil association studies**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       

  Amick et al. ([@B53])                                                                                                                                                                                                        Unclear time frame post-TBI (from 4 to 122 h after injury)                                          IL-2, IL-4, IL-6, IL-12                                                                                                               Highly variable; barbiturates and various ICP/CPP-directed therapies                            GOS at 6 months post-Injury                                                                                                                                             IL-6 and IL-12 were increased compared to control group                                                                                                                                                                                                                                               No association between IL-2, IL-4, IL-6, and IL-12 with GOS at 6 months

  Banked samples from a non-TBI control group (*n* = 12); CSF gained from investigations for meningitis                                                                                                                        No correlation between measured CSF cytokines and GOS                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       

  Buttram et al. ([@B54])                                                                                                                                                                                                      Collected 18, 24, 48, and 72 h post-injury                                                          IL-1a, IL-1b, IL-2, IL-4, IL-5, IL-6, IL-7, IL-8, IL-10, IL-12p70, IL-13, IL-15, IL-17, IP-10, eotaxin, TNF-a, INF-g, MCP-1, MIP-1a   Not well specified; half the groups was subjected to moderate hypothermia for 48 h (32--33°C)   Dichotomized GOS at 6 months                                                                                                                                            Cytokine levels in TBI patients were significantly higher compared to controls                                                                                                                                                                                                                        There is no association between CSF cytokines and outcome at 6 months

  No association between CSF cytokines and outcome                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       

  Csuka et al. ([@B55])                                                                                                                                                                                                        Daily until EVD removal                                                                             IL-6, IL-10, TNF-a, TGF-B1                                                                                                            Unclear ICP/CPP-directed therapies                                                              Outcome: GOS at 3--6 months\                                                                                                                                            IL-10 was found in both CSF and serum during the measurement period                                                                                                                                                                                                                                   CSF cytokines do not correlate to outcome at 3--6 months
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         No correlation found between cytokines and outcome\                                                                                                                                                                                                                                                                                                                                                                                                                           
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         ICP: no correlation between cytokines and ICP                                                                                                                                                                                                                                                                                                                                                                                                                                 

  CSF cytokines do not correlate to ICP                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       

  Diamond et al. ([@B56])                                                                                                                                                                                                      q12 h for 6 days                                                                                    IL1b                                                                                                                                  Not specified                                                                                   EEG and Epileptologist defined PTE                                                                                                                                      Serum IL-1b levels was associated with PTE                                                                                                                                                                                                                                                            CSF IL-1b levels within the first week of injury is not associated with PTE

  CSF IL-1b was not statistically associated with PTE                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       

  Goodman et al. ([@B57])                                                                                                                                                                                                      Unclear sampling interval                                                                           IL-1, IL-6, IL-8, IL-10, IL-12, TNF                                                                                                   Not specified                                                                                   ICP/CPP: no correlation between CSF cytokines and ICP or CPP                                                                                                            Serum and CSF IL-6 and IL-8 were both elevated consistently                                                                                                                                                                                                                                           CSF cytokines are not associated with changes in ICP and CPP

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       

  Gopcevic et al. ([@B58])                                                                                                                                                                                                     Unclear sampling interval                                                                           IL-8                                                                                                                                  Not specified                                                                                   30-day in-hospital mortality: no correlation between CSF IL-8 levels and patient outcome                                                                                No correlation between plasma and CSF IL-8 levels                                                                                                                                                                                                                                                     CSF IL-8 is not associated with in-hospital mortality at 1 month

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       

  Lenzlinger et al. ([@B59])                                                                                                                                                                                                   Daily for unclear duration                                                                          sIL-2R, B2M, neopterin                                                                                                                Unclear ICP direct therapy                                                                      GOS at 4--6 months                                                                                                                                                      Neopterin levels were higher in CSF than serum                                                                                                                                                                                                                                                        sIL-2R, B2M, and neopterin in CSF have no correlation to outcome at 4--6 months

  No association between measured cytokines and outcome                                                                                                                                                                        B2M and sIL-2R levels were higher in serum                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       

  Maier et al. ([@B60])                                                                                                                                                                                                        Admission and daily up to day 10                                                                    sTNFRp55, sTNFRp75                                                                                                                    Not specified                                                                                   GOS at 6 months                                                                                                                                                         sTNRFp55 and STNFRp75 is elevated in CSF compared to control                                                                                                                                                                                                                                          sTNFRp55 and sTNFRp75 CSF levels are not associated with outcome at 6 months

  No correlation between sTNFRp55 or sTNFRp75 and outcome                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       

  Maier et al. ([@B61])                                                                                                                                                                                                        Admission and daily up to day 14                                                                    IL-6, IL-8, IL-10                                                                                                                     Not specified                                                                                   Mortality at unspecified interval\                                                                                                                                      IL-6 and IL-8 were directly correlated with each other with CSF level higher than serum                                                                                                                                                                                                               CSF IL-6, IL-8, and IL-10 levels do not correlated with mortality
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         No correlation between CSF cytokines and patient outcome                                                                                                                                                                                                                                                                                                                                                                                                                      

  All measured cytokines were higher in TBI patients compared to controls                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       

  Morganti-Kossmann et al. ([@B62])                                                                                                                                                                                            Unclear sampling interval                                                                           IL-2, IL-4, IL-6, IL-10, TNF, IFN, GM-CSF                                                                                             Not specified                                                                                   Unclear outcome scale at unspecified interval                                                                                                                           IL-6 is higher in focal injury patterns                                                                                                                                                                                                                                                               CSF cytokines are not associated with patient outcome

  No clear association between CSF cytokines and outcome                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       

  Newell et al. ([@B63])                                                                                                                                                                                                       q12--24 h for 7 days                                                                                sIL-2Ra                                                                                                                               Not specified                                                                                   Dichotomized GOS at 6 months (good = 4 or 5; poor = 3 or less)                                                                                                          sIL-2ra levels during the measurement period were no different between TBI and controls                                                                                                                                                                                                               sIL-2Ra isn't significantly elevated post-TBI and does not correlate with outcome

  No association between sIL-2Ra and outcome                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       

  Ross et al. ([@B64])                                                                                                                                                                                                         Unclear sampling interval                                                                           TNF-a                                                                                                                                 Not specified                                                                                   GOS at 6 months\                                                                                                                                                        TNF-a in CSF and serum were both elevated                                                                                                                                                                                                                                                             CSF TNF-a displayed no association with patient outcome at 6 months
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         No correlation between TNF-a and outcome                                                                                                                                                                                                                                                                                                                                                                                                                                      

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       

  Uzan et al. ([@B65])                                                                                                                                                                                                         At 6--10, 20--28, 40--56, and 64--74 h post-injury                                                  IL-8                                                                                                                                  Unclear ICP/CPP-directed therapies                                                              GOS at unspecified interval                                                                                                                                             N/A                                                                                                                                                                                                                                                                                                   CSF IL-8 level within the first 2--3 days are not associated with outcome

  No correlation between CSF IL-8 and patient outcome                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  
  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

*TBI, traumatic brain injury; sTBI, severe TBI; GOS, Glasgow outcome scale; CMD, cerebral microdialysis; RCT, randomized control trial; ICP, intracranial pressure; CT, computed tomography; PbtO~2~, brain tissue oxygen monitoring; CPP, cerebral perfusion pressure; CSF, cerebrospinal fluid; LPR, lactate:pyruvate ratio; DC, decompressive craniectomy; μmol, micromolar; mm Hg, millimeters of mercury; L, liter; μmol, micromolar; IL, interleukin; a, alpha; b, beta; g, gamma; TNF, tumor necrosis factor; INF, interferon; MCP, monocyte chemoattractant protein; MIPs, macrophage inflammatory proteins; TGF, transforming growth factor; NGF, nerve growth factor; BDNF, brain-derived neurotrophic factor; GDNF, glial derived neurotrophic factor; TNFR, tumor necrosis factor receptor; GM-CSF, granulocyte macrophage colony stimulating factor; sVCAM, soluble vascular cell adhesion molecule; sICAM, soluble intracellular adhesion molecule; PDGF, platelet-derived growth factor; VEGF, vascular endothelial growth factor; MDC, macrophage derived chemokine; FGFR, fibroblast growth factor receptor*.

Bias Assessment {#S2-6}
---------------

As the goal of this review was to produce a systematically conducted scoping review of the available literature on CMD and CSF cytokine measures in sTBI, formal bias assessment was not done. Our desire was to produce a comprehensive overview of the current literature on the topic of CMD/CSF cytokines in sTBI. Formal evidence grading was not conducted (given the limited and heterogenous literature body), and thus we deemed formal bias risk assessment unnecessary for this emerging area of literature, which clearly suffers from standard biases associated with new areas of clinical research.

Statistical Analysis {#S2-7}
--------------------

A meta-analysis was not performed in this study due to the heterogeneity of data and study design within the articles identified.

Results {#S3}
=======

Search Strategy Results {#S3-1}
-----------------------

### CMD Cytokine Search {#S3-1-1}

Results of the search strategy for CMD cytokines in sTBI is shown in the flow diagram in Figure [1](#F1){ref-type="fig"}. In total, 259 articles were identified, with 255 from the database and 4 from meeting proceeding sources. After removal of the duplicates, there were 144 articles left for assessment in the first filter of title and abstract. Thirty-seven articles passed the first filter, requiring acquisition of the full manuscript to assess inclusion eligibility. After assessing the full manuscripts, 19 articles were deemed eligible for final inclusion in the scoping systematic review. No articles were added from the reference sections of either review papers or the parent manuscripts included in the systematic review.

![Flow diagram of search results for cerebral microdialysis review.](fneur-08-00331-g001){#F1}

### CSF Cytokine Search {#S3-1-2}

The search strategy flow diagram for the CSF cytokine scoping systematic review is shown in Figure [2](#F2){ref-type="fig"}. Overall, 3,218 articles were identified, with 3,214 from the database search and 4 from published meeting proceedings. There were 1,317 duplicates removed, leaving 1,901 references to review in the first filter. Applying the inclusion/exclusion criteria to the title and abstract of these articles, 105 manuscripts were selected for review of the full article. One additional reference was added from the reference sections of review papers. During the second filter of the full manuscript, 36 met the final inclusion criteria for the scoping systematic review. Remaining articles were excluded due to non-relevance.

![Flow diagram of search results for cerebrospinal fluid review.](fneur-08-00331-g002){#F2}

Patient/Study Demographics {#S3-2}
--------------------------

### CDM Cytokine Review {#S3-2-1}

Of the 19 articles included in the CMD cytokine portion of the systematic review ([@B11]--[@B19]), 15 were formal manuscript publications ([@B14]--[@B24], [@B26]--[@B29]) and 4 were meeting abstract publications ([@B11]--[@B13], [@B25]). There were 13 prospective studies ([@B13]--[@B16], [@B18]--[@B21], [@B25]--[@B29]), with 12 prospective observational studies ([@B13]--[@B15], [@B18]--[@B21], [@B25]--[@B29]) and 1 prospective randomized control trial ([@B16]). Four studies were retrospective case series or database reviews ([@B11], [@B20], [@B22], [@B23]). Finally, two studies were of "unknown" study design given a lack of information available within the methods ([@B12], [@B24]).

The study population described in CMD cytokine papers was generally poorly characterized sTBI patient populations, undergoing various ICU and surgical therapies for their heterogeneous intracranial pathology ([@B11]--[@B15], [@B18]--[@B25], [@B27]--[@B29]). Three studies focused on only those patients with imaging defined "diffuse" brain injury, without extra-axial or large focal intraparenchymal lesions ([@B16], [@B17], [@B26]).

A total of 267 unique patients with sTBI were described across the 19 studies included in the CMD cytokine review. Thirty-six patients were "diffuse" sTBI only ([@B16], [@B17], [@B26]), with the remaining being unspecified heterogeneous sTBI pathology. We believe that some of the studies included within this portion of the review may contain duplicate patient information, as marked in Tables [1](#T1){ref-type="table"} and [3](#T3){ref-type="table"}. Multiple publications from the same research groups likely were conducted on the same patient populations, yielding unique and separate manuscripts on the same group of patients. Though we must acknowledge it was difficult to determine, in some circumstances, whether CMD cytokine analysis was being conducted on new patient groups or existing banked samples from previous prospective studies. With that said, our goal for the CMD cytokine scoping review was to provide an overview of all available literature in the area, hence we have included all published papers on CMD cytokines in sTBI within this review.

### CSF Cytokine Review {#S3-2-2}

Of the 36 articles included in the CSF cytokine systematic review ([@B20]--[@B65]), 32 were formal manuscript publications ([@B30]--[@B36], [@B39], [@B40], [@B42]--[@B61], [@B63]--[@B65]) and 4 were meeting abstract publications ([@B37], [@B38], [@B41], [@B62]). There were 34 prospective studies, all being observational studies ([@B30]--[@B61], [@B64], [@B65]). One study was a retrospective case series ([@B63]). Finally, one study had insufficient information to determine the design ([@B62]).

The populations described with in the CSF cytokine studies were almost all sTBI patients with unspecified heterogeneous injury patterns. Three studies documented the inclusion of both moderate-severe patients within the methods ([@B39], [@B53], [@B62]). We were unable to separate the moderate and sTBI patients within these studies, hence they were all included in the final descriptive statistics.

A total of 1,363 patients were described across all studies included in the CSF cytokine systematic review. The mean age for each study cohort varied significantly across studies. Twenty-one studies included pediatric patients within their studies, either as the primary population of interest or included with adult patients ([@B31]--[@B35], [@B42], [@B44], [@B47]--[@B50], [@B52], [@B54], [@B55], [@B57], [@B59], [@B60], [@B63]--[@B65]). Therapies received by these patients while in the ICU varied significantly, with profound heterogeneity in treatment provided. Details surrounding patient cohort, study design, and concurrent therapies can be found in Tables [2](#T2){ref-type="table"} and [4](#T4){ref-type="table"}. We made substantial efforts to exclude duplicate patient data across studies. However, given that many of the papers came from centers of excellence for TBI research, some of the patient data may be cross reported in multiple studies. This could reduce the total overall number of unique patients. It was impossible based on the information provided within the parent studies to tease out all patients which were reported more than once.

Cytokine Measurement Technique {#S3-3}
------------------------------

### CMD Cytokine Review {#S3-3-1}

Location of the CMD catheter was the following: mixed healthy/peri-lesional tissue in six studies ([@B11], [@B13], [@B15], [@B21]--[@B23]), peri-lesional in six studies ([@B14], [@B16]--[@B19], [@B28]), healthy tissue in two studies ([@B27], [@B29]), and unknown tissue location in five studies ([@B12], [@B20], [@B24]--[@B26]). Some studies utilized paired microdialysis catheters, one in healthy and one in peri-lesional tissue ([@B13], [@B15], [@B22], [@B23]). One study evaluated two catheters in one location ([@B18]). Analysis interval for CMD samples was as follows: every 6 h in 12 studies ([@B14]--[@B24], [@B27]), every 8 h in 1 study ([@B26]), every 3 h in 2 studies ([@B28], [@B29]), and unspecified in 4 studies ([@B11]--[@B13], [@B25]). The duration of sample collection varied as well, with the typical collection period of 5--7 days.

Numerous different panels of cytokines were evaluated within the CMD samples, across the studies included within the review. The most commonly studied cytokines included IL-1b, IL-1ra, IL-6, IL-8, and IL-10. Details of CMD technique and catheter locations are listed in Table [3](#T3){ref-type="table"}.

### CSF Cytokine Review {#S3-3-2}

Sampling of CSF was conducted through external ventricular drains (EVDs) in almost all patients described within the studies included in the CSF cytokine systematic review ([@B30]--[@B65]). Sampling and analysis frequency varied significantly from study to study with sampling occurring from every 6 h to daily. Duration of sampling varied as well, up to 21 days post-injury ([@B35]).

Like the CMD cytokine papers, the CSF cytokine papers included in this review reported the measurement of various cytokines. The most commonly measured cytokines in CSF reported were IL-1b, IL-1ra, IL-6, IL-8, IL-10, and TNF. The details of CSF sampling and specific cytokines measured can be found in Table [4](#T4){ref-type="table"}.

Outcomes {#S3-4}
--------

### CMD Cytokine Review {#S3-4-1}

Given that the CMD cytokine portion of this review was a scoping review of all the literature on CMD cytokines in sTBI, the goals and outcomes reported by the studies were heterogenous, and are listed in Table [3](#T3){ref-type="table"}.

Only one study described an intervention during the assessment of CMD cytokines. This study was a prospective RCT describing the application of subcutaneous rhIL-1ra post severe diffuse TBI ([@B16]). The results described both elevated CMD IL-1ra levels and a reduction in MDC in the IL-1ra treated group. The follow-up retrospective statistical analysis of all CMD measured cytokines described a trend toward an increase in M1-microglia related cytokine activation following administration of rhIL-1ra ([@B17]).

Three studies reported the correlation between CMD cytokines and patient outcome ([@B11], [@B20], [@B29]). Two studies reported a positive association between elevated CMD IL-6 and improved survival, with one describing improved Glasgow Outcome Scale (GOS) at 6 months (*p* = 0.03). One study reported the negative correlation between CMD IL-1ra and poor GOS at 6 months (*p* = 0.018).

Most studies reported the CMD cytokine profile post-TBI and temporal fluctuations ([@B12], [@B14], [@B15], [@B21], [@B24], [@B26], [@B27]). Given the myriad of cytokines measured across the studies, it is impossible to describe all of the relationships. Highlighted details can be found in Table [3](#T3){ref-type="table"}. The main findings included elevated IL-1b, IL-6, and IL-8 within the first 48--72 h post-injury, with these cytokines also displaying peaks during these times ([@B21]--[@B23]). The CMD IL-10 levels were found to be more uniformly elevated during the sampling periods ([@B22], [@B26]). Finally, some coexpression relationships were found between IL-1b with TNF, IL-1ra with IL-1a, and MIP-1a with MIP-1b ([@B14]).

Two studies evaluated the CMD cytokine profile associated with secondary events while in the ICU ([@B18], [@B19]). CMD IL-6 levels were positively associated with episodes of ischemia/metabolic stress, as defined by a lactate:pyruvate ratio greater than 30 and glutamate levels greater than 80 μmol/L.

The relationship of catheter location to CMD cytokine levels was discussed in a couple of papers, with peri-lesional tissue displaying higher cytokine expressions than distant or healthy tissue locations ([@B11], [@B13]). Evaluation of catheter technology ([@B18]) and cytokine measure feasibility ([@B28]) were also described in a few studies.

### CSF Cytokine Review {#S3-4-2}

The 36 papers included in the CSF systematic review ([@B30]--[@B65]) included both manuscripts, which reported positive associations between CSF cytokine levels and neurophysiologic or patient outcome ([@B30]--[@B52]), and studies reporting no association ([@B53]--[@B65]) (i.e., "nil association") between CSF cytokines and the outcomes of interest for the CSF cytokine systematic review. No studies reported an association, "nil" or otherwise, between CSF cytokine measures and tissue outcome as assessed by follow-up neuroimaging. The subsections below describe more details of these outcomes of interest, with further information found in Table [4](#T4){ref-type="table"}.

#### Positive Association Studies {#S3-4-2-1}

Twenty-three papers included within the CSF cytokine review found associations between cytokine levels and both neurophysiologic and patient outcomes. Twenty-one described the association between CSF cytokines and patient outcome ([@B30]--[@B50]). Five papers discussed the association between CSF cytokine measures and neurophysiologic outcomes ([@B36], [@B48], [@B49], [@B51], [@B52]).

##### Patient Outcome {#S3-4-2-1-1}

Cerebrospinal fluid levels of several cytokines were related to functional patient outcomes. The most common outcomes specified were: overall mortality or GOS at 6--12 months post-injury. The strongest relationships between cytokines and patient outcome were for IL-1b, IL-1ra, IL-6, IL-8, IL-10, and TNF.

A strong positive correlation between CSF measured IL-6 and IL-8 with poor GOS was the most commonly described relation between CSF cytokines and patient outcome ([@B30], [@B32], [@B35], [@B36], [@B42]--[@B47], [@B49], [@B50]). Similarly, a strong association between elevated CSF measured IL-10 and poor patient outcome was described in five studies ([@B31], [@B41], [@B46]--[@B48]). Elevated CSF IL-1b was found to be associated with mortality and worse GOS at 6 months in four studies ([@B33], [@B34], [@B36], [@B49]). Finally, CSF TNF-alpha (TNF-a) levels were found to be associated with worse patient outcome in two studies ([@B30], [@B46]).

The relationship between CSF cytokine levels and neuropsychiatric outcome was described in four studies ([@B37]--[@B40]). These associations included: higher IL-6 and IL-8 were associated with a higher incidence of depression at 6 months ([@B37]), TNF-a levels with depression at 12 months ([@B37]), IL-5/IL-8/IL-12/TBF with apathy at 12 months ([@B38]), TNF-a with disinhibition at 12 months ([@B39]), and sVCAM/sICAM/sFAS with depression at 6 months ([@B40]).

##### Neurophysiologic Outcome {#S3-4-2-1-2}

Three studies discussed the correlation between CSF cytokine levels and ICP/CPP ([@B36], [@B48], [@B52]). Elevated IL-6 and IL-8 levels were associated with increased ICP and decreased CPP in one study ([@B52]). Elevated CSF IL-1b was associated with increased ICP in two studies ([@B36], [@B48]). One study found an association between CSF IL-6 and IL-8 levels and reduced middle cerebral artery (MCA) CBFV ([@B51]). Finally, one study found an association between IL-6 levels and the mean change in somatosensory evoked potential over 96 h recording window ([@B49]).

#### Nil Association Studies {#S3-4-2-2}

Our review identified 13 studies documenting a "nil association" between CSF measured cytokines in sTBI patients and various outcomes of interest ([@B53]--[@B65]). Eleven studies reported no association between various CSF cytokines and patient outcome, as reported by in-hospital mortality or GOS at 3--6 months ([@B53]--[@B55], [@B58]--[@B65]). The cytokines reported within these studies varied significantly, with the most common "nil associations" reported for IL-1b, IL-6, IL-8, IL-10, TNF-a, and sTNFR. A total of 376 patients were described within these studies. Two studies reported no association between CSF cytokine measures and ICP/CPP ([@B55], [@B57]), while one study failed to determine an association between CSF IL-1b and post-traumatic epilepsy ([@B56]). Further detail on the "nil association" studies can be found at the bottom of Table [4](#T4){ref-type="table"}.

Complications {#S3-5}
-------------

Within the CMD cytokine manuscripts, the majority failed to report whether complications were considered within the data collection. Only three papers disclosed complication reporting ([@B18], [@B28], [@B29]), with two reporting "no complications" ([@B28], [@B29]), and one reporting a CMD catheter malfunction in one patient ([@B19]). The complication profiles may be under-reported within the CMD studies. Complication reporting within the CSF cytokine studies was essentially non-existent, with the focus of these studies the association between CSF cytokine measures and various outcomes.

Discussion {#S4}
==========

CMD Cytokines in sTBI {#S4-1}
---------------------

Our scoping systematic review completed for CMD cytokine measures in sTBI allows limited conclusions. Despite 19 publications ([@B11]--[@B29]), this literature is based on very small numbers of patients with many studies conducted on the same patient populations with banked CMD samples. However, the limited conclusions are important. First, CMD-based measurement of cytokines is feasible. Second, CMD catheter location makes a difference in the levels of cytokines measured, with peri-lesional tissue producing high levels compared to distant or healthier tissue ([@B11], [@B13]). Third, peaks in CMD cytokine measures may occur within the first 48--72 h for IL-1b, IL-6, and IL-8 ([@B21]--[@B23]). Interestingly, IL-10 seems to remain elevated in CMD samples through the duration of the sampling periods described ([@B22], [@B26]). Fourth, IL-6 levels may prove to be predictive of ongoing second insults such as ischemia ([@B18], [@B19]). Fifth, the data from the rhIL-1ra studies ([@B16], [@B17]) shows that subcutaneous rhIL-1ra leads to both an increase in CMD IL-1ra and a modulation of microglial/macrophage based cytokine profiles. Sixth, CMD IL-1b/IL-1ra/IL-6/IL-8 may be associated with poor outcome ([@B11], [@B20], [@B29]), up to 6 months post-injury. Finally, complications related to the use of CMD catheters are likely to be under-reported.

CSF Cytokines in sTBI {#S4-2}
---------------------

Our systematic review of CSF cytokines in sTBI, focused on the association between cytokine measures and patient, tissue outcome, or neurophysiology outcomes identified some interesting trends. First, a large number of heterogeneous studies correlated CSF cytokine levels with patient outcome, defined as either mortality or GOS at 6--12 months post-injury. Various large panels of cytokines were described within these studies, but the strongest associations with outcome were found for IL-1b, IL-1ra, IL-6, IL-8, IL-10, and TNF. Most studies described an association between elevated levels of these cytokines and poor GOS/increased mortality. Second, psychiatric outcome at 6--12 months post-injury appears to have some association to CSF cytokine levels ([@B37]--[@B40]). Elevated CSF IL-6, IL-8, and TNF seem to have the strongest associations with depression, apathy, and disinhibition at 6--12 months. Third, analysis of the impact of CSF cytokine levels on neurophysiologic measures is limited, with only five studies documenting such data ([@B36], [@B48], [@B49], [@B51], [@B52]). The strongest relationship identified here was the link between elevated levels of various cytokines, such as IL-6 or IL-1b, and elevated ICP ([@B36], [@B48], [@B52]). Further work is required before robust conclusions can be drawn in this area. Fourth, none of the studies explored the link between CSF cytokine measures and tissue outcome, as assessed by follow-up neuroimaging. Fifth, despite the "positive" associations found in the previously described papers, 11 manuscripts found no relationship between CSF cytokines and patient outcome ([@B53]--[@B55], [@B58]--[@B65]). The patient numbers in the individual studies, which reported no associations was much smaller than that in the studies describing a positive association between CSF cytokines and patient outcome (mean of 28 vs. 41 patients/study, respectively), making lack of power a possible cause of a negative result. Further patients in the "nil association" studies represented an overall smaller sample, totaling 376 patients vs. 948 patients in the "positive association" studies. Finally, complication reporting within the CSF cytokine studies was absent. Selective reporting bias here is a major concern.

Limitations {#S4-3}
-----------

Despite the interesting results of these two systematic reviews, there are significant study limitations, which need to be highlighted. Limitations with each separate review can be found within the subsections to follow.

### CMD Cytokine Review {#S4-3-1}

First, there were a small number of heterogenous studies found for the CMD review, with some manuscripts reporting on the same patient populations based on banked CMD samples. Most of these studies had patient cohort with unspecified heterogeneous patterns of injury in the setting of sTBI. The exceptions were the studies describing "diffuse" TBI patients only. These drawbacks limit the generalizability of the results to all patients with sTBI. Second, the ICU and surgical therapies received by these patients during CMD sample collection/processing was quite heterogeneous and poorly reported, and could have driven substantial variation in CMD cytokine measures. Third, there were variations in CMD catheter location between studies. This could impact the CMD cytokine measures obtained and the described relationships. Fourth, complications association with CMD monitoring was seldom reported. We believe there is significant selective harms reporting. Finally, given the studies and results identified for the CMD review, there is likely a large publication bias, favoring only studies with positive results.

### CSF Cytokine Review {#S4-3-2}

First, there were many quite heterogeneous studies identified in the CSF cytokine review. The included papers varied by study design, number of patients, patient inclusion criteria, ICU-based therapies offered/provided to patients, blinding during outcome assessment, and primary outcome of the studies. Information regarding the relationship between CSF cytokine measures and patient outcome was often buried within the text, and often not an explicit target for the study. Furthermore, selective outcome reporting with regards to individual CSF cytokine measures and their association to patient outcome was present in many studies. Thus, the conclusions that can be drawn from these studies and the strength of associations between CSF cytokines with patient outcome/neurophysiologic outcome are limited. Second, selective outcome reporting was an issue in many studies with preference to reporting significant association(s) only, making no reference to other CSF measures and the results of statistical analysis. Third, complication reporting was concerning within the literature identified (as mentioned above). Significant underreporting is suspected, with selective harms reporting the likely cause. Fourth, given all the above limitations and heterogeneity issues, a meta-analysis was not performed. Finally, though majority of studies report a positive association between cytokine levels and outcome, given that this is an emerging area of research, it is important to consider whether this might represent a publication bias toward positive studies.

### Correlation with Clinical Parameters {#S4-3-3}

Several studies attempt to correlate a specific mediator concentration with outcome. As these mediators are known to act in complex cascades and show a high degree of statistical collinearity, simple inferences cannot be made about the role of a given mediator in causing a particular outcome or relating to a clinical parameter such as ICP. As these mediators are induced by the initial traumatic insult, they are all confounded by severity of injury: it is, therefore, not surprising that a high concentration of cytokine relates to a worsened clinical parameter. Furthermore, the timing of monitoring in relation to the time of injury is not consistently reported. Several mediators, such as IL6, can have differing biological effects depending on the milieu in which they are produced ([@B68]). Finally, many mediators are known to act in concert and regulate the same downstream pathways (e.g., IL1b and IL1ra) such that measuring a mediator in isolation does not reflect its true biological role, which is time and milieu dependent.

Future Directions {#S4-4}
-----------------

Given the significant heterogeneity in both study design, patient injury patterns, ICU/surgical treatments, and CMD/CSF cytokine measures identified within both systematic reviews, there is substantial room for more investigation into this emerging area of the literature in sTBI.

Although it is tempting to simply suggest that larger studies are done to overcome the heterogeneity in injury patterns following TBI, there are significant limitations to this approach. There are an ever-expanding list of mediators available for analysis over multiple time points in a range of biological fluids and without a robust understanding of the interaction between these mediators, it is unlikely that a meaningful pattern will emerge through brute force of numbers. More refined approaches that explore within patient comparisons with multiple sites of monitoring ([@B69]), interventional studies in which specific modulation of a biological pathway ([@B16]), and more sophisticated multivariate statistical methods ([@B14]).

Some studies have attempted to relate intensive care parameters such as ICP to the cytokine and chemokine response to TBI ([@B26]). This is not a simple relationship as the time frame over which cytokines and chemokines are produced occur over several days and weeks, rather than over the minutes and hours. There is insufficient evidence to stipulate, which intensive care interventions should be applied during monitoring of inflammatory mediators; however, it is important for individual studies to report their intensive care protocols and interventions.

As CMD is necessarily focal in nature, strict reporting of the method of localization is required and ideally 2 catheter studies, 1 in peri-lesional tissue and 1 in healthy tissue provides the most informative data (quote consensus paper).

When multiple mediators are measured, multivariate statistical methods must be employed, such as multivariate projection methods in order to model the potential interactions ([@B14], [@B70]).

This could potentially identify cytokine patterns of coexpression in CMD and CSF, highlighting target for future studies and therapeutic targets.

One deficit in the current CMD literature is complication reporting. In part, this relates to the difficulty in apportioning complications to CMD catheter insertion specifically. As patients will have invasive monitoring for ICP monitoring and brain tissue oxygenation in any circumstance for directing clinical therapy, the additional risk of inserting CMD through an existing cranial access device is small and difficult to quantify. Nevertheless, transparency dictates that complications are reported. Standardization of the methodologies employed allows multicenter prospective evaluation of cytokines within CDM and CSF and is necessary to improve patient recruitment and aid with spreading the substantial cost of cytokine analysis among centers. Without this collaboration, the limitations with single center recruitment and costs of cytokine processing in CMD and CSF limits the ability to combine datasets across units and studies. This would allow easier compilation of data sets and may add clarity to the associations highlighted within this manuscript. Finally, a consideration of the methodological factors that determine microdialysis catheter efficiency, including choice of perfusion fluid, catheter membrane, and pump flow rate all have an impact on the result obtained.

Conclusion {#S5}
==========

The evaluation of CMD and CSF cytokines is an emerging area of the literature in sTBI. The two scoping systematic reviews have demonstrated a limited literature available on CMD cytokine measurement in sTBI, with some preliminary data supporting feasibility of measurement and associations between cytokines and patient outcome. Second, a number CSF cytokine levels may be associated with patient outcome at 6--12 months, including IL-1b, IL-1ra, IL-6, IL-8, IL-10, and TNF. Third, there is little to no literature to date in support of an association between CSF cytokines and neurophysiologic or tissue outcomes. Ultimately, the aim of CMD monitoring of inflammatory mediators is to reveal the underlying pathophysiology of TBI rather than as a clinical tool.
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